{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system",
      "version": "1.0.0",
      "authors": "Rana Aldisi",
      "description": "This document contains the curation of the review article Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system by Taly et al. 2009"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/7e4be528f12abd28be768b62402fba6e083eaf9e/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/taly2009.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta polypeptide 42",
      "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "calcium(2+)",
      "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "gamma-aminobutyric acid",
      "id": "9583f9418a889245078b43a5744b3aee37f76bff3bff369f21f4091c2ad475d69415b09ff3b3b7e7aa6014f4e5dab6706477099218ce8a665f6751daba94e6b3"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutamate(2-)",
      "id": "9749d43ec7dd166b90348b70de96bca3f824fa7c4624aa5f0d82f2dbd2e1d559cccd5b7e74c86268f2e152cea542c1a7c99fc9b98d5d12853d44f9a56b615e4a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "zinc(2+)",
      "id": "94b0a4e4ea78da28e3f49e25ef431d498faa0597cfb5df72a4dd991157c2f6bc3e054c807617cc70ee1304f5d5f5142c4115acb575de09b30f40f464b96c2d97"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Mecamylamine",
      "id": "f81a5cca79277a3483157d6067c10b7916d6c4e183c85db0a42f5f427ebe2280a46a47f3899a13dfa89025b0f2b6dd3a0b02b3240d27c1c06be3d4a662516041"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetylcholine",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "cholesterol",
      "id": "7faee5b47a8041968f11e54fbeaf6513bd4bca4742da80dfacbb3c825bd402c8a2aaeeeaa4467b4dbe74d2420f5a35b5bcf04f081920d49313061af201853c74"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "choline",
      "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "clozapine",
      "id": "fb42e7acad72c89f782055833a2fb598e65ed69dd80ca9f990cb7eed7b8f502646c6d7ded82c76a3f04e865eb312f70e08c64de3c19000595df344857537ac94"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "dopamine",
      "id": "70f7314679db5bae3c2260b6feff9a6ef3407fb6a585f92a58c59fd066a2ec279c0091a72edba3465c4f2aa033afff7fded0b16c4a84f4bbcecd092a934ea66e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "fluoxetine",
      "id": "6b1774663dff99edf84e4b4ec084f2f80bda20579a83069083af7210d38d03faafdded3b7c49ef0243b4e387815d25dfb7abf8adf62388ff395dc8df6973aa2b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "galanthamine",
      "id": "829d639ffa1b9cf0dc884553079510b093dde8971a129c58afff24ea1d1103f0db214945577b66dc941db450715ecdfe7951a8498afafb02cb1653b60845fc57"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "monoamine",
      "id": "16634fcf3787bb9a6bb992bb960f329f391a3e99fe4ae899a9a272ab7bdbf3dfafd6d7be02a29f61e6beebf68f94a1f915e157e411e5d1a826826470dca8812d"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nefazodone",
      "id": "7b975992f08bc038de14ee5b2a2c8fe179c17e2666ad99df329f9f7ce182a24f8e415c0298b70b4ab1764cd075398315f9f0c165ced17fd1d3175df718ba0b9b"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotine",
      "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nisoxetine",
      "id": "c67bca65069e59b5f0342fe1b03a9f179fb7ac2dffebe2c0a0ba6ad6c563ae6c7a1274cd4cd1f22b3860478e5026a37d2bf4d81a63e72e9bd67e786d1b77fdb4"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nomifensine",
      "id": "1dc4b4301f14a9080314127ef11d7632302f3f6f7b1185ebcce93524c92f333fc5570ad92209a5ccae64afe00a812c6239be248982c97bad16ae4f1791eae93e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "paroxetine",
      "id": "94e1f63122f083ad7f765b32c7a9c33ac6c4a800d2b4a4a20ecef1c78785323803364c9ccc72932f9219369b9daa156231f8544d498765bf295e80a5e96b4f33"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "scopolamine",
      "id": "3a1bb34f4041183c02d322a9719f3efbadef9bf26804f46b729cd13c9107e3b2fe500006cdd50e18fd01abeca0a45aca2a8475a44a9f978315c17023fe186bd0"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "serotonin",
      "id": "8d7ceea95cec905de8941facf48d632e3c509b6ce451f835af1fab5789daacc5bbf8d1bdb7cfd90863a70871a9a9a07b093896248712aa6567895ae8cf3b3502"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "sertraline",
      "id": "be771a14feafd3f9034014b35aa5a57ea36fad40f11df3dcf99ad96a5f3e79c71ab363cccd3abcb05ba8c1468fb22ab262b47227ccd139b146649cc5101197b6"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "tropisetron",
      "id": "28a4035d409cc4435dfaec89a934c38e3d5323029539ee212a78cfea07d8248bf5b4b6c85c00b4593bb760a3f90cfc39b28302a1d7949bea261a1560ee9ec74e"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "vanoxerine",
      "id": "5bc3a5554d994ad2f709e901a4cd24d0008e0dee683ce3939aa977c17aaf89a53ae8f6b5700f9e72d098b168cd42b418844f31839e9fd50382025680b6346cdc"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "varenicline",
      "id": "fed219893919839171faea135762f0569613737568e5ee2f418d4d35e15b2c2b2ff5a03fa842e7ff502861611d5d9c4e6140c30de785caa9448a00929f49a6a7"
    },
    {
      "function": "Abundance",
      "namespace": "DRUGBANK",
      "name": "Facinicline",
      "id": "cfa27e7b3c4bcc87d95036c026cfea31b2bc97aafabaf9773185d027efe54f2bc18907362c82f9656cf7192b2fb1010d8b299574c294f7eeff9bf232d7708ce2"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea",
      "id": "a75ecdb78550ad514739cfaa7497d3645518a18a1b70f4028abb0f28616411d3caff926693c2bf718124fcdb9c8509cf048900c9174e2ab0450c8ffc30269e6d"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "3-(2,4-dimethoxybenzylidene)anabaseine",
      "id": "70d043407607730d6cb5b34ab57b87b6dbbad8bf519eeab54e856238fe430c47656ad76461ac9515345df6ebbd7e5e8e81fb34ac62e0fd7b2cf89a420d0632fe"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo(3.2.0)heptane",
      "id": "f5c877d1413412a30087f8e59618aaedbc6f4964d9a4c73d84ca8fce7423e64d46ec334c24cba953a2b024b63382ddbd07684fecc69cda8d4bfff0ab5e857957"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole",
      "id": "7aff32ff6bd8b166134920129943a972efd30210691f5e270725ba1f94ec7a7df50383f75d9f1cbf31621f3b50251be5b86679c86da748a981884a3d294857fa"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "5-(2-azetidinylmethoxy)-2-chloropyridine",
      "id": "8532912318df2c950df89d266a072a0f690f68f47e5ef1af9861b1d57534bd4a92361e7b74352cf36bf1b095969aaaba6e5ab5e45440c6ac7b9bfcde1da7bafc"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "AR-R 17779",
      "id": "27dac0a0e7cd1ef9c7351e601fd3894ecfc2524a4a9f74b691bf87db21cfd44015d6d4930f8da8f841a85f6a61f06bd4eb04ca91c402cbfb3235bc523248eb0d"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Central Nervous System",
      "id": "1fe0c06a1530f3b8af3f023bf0ce521de8876c8c1b0f155dcea151c3fdd6742554432e6dbb7aa73df3e5bb75d304f288726f4c7510fbbcb0854947b7e2a9763e"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Dihydro-beta-Erythroidine",
      "id": "ffc5021fdc725a48a185594f5c5bb68b41bcf9e1fb3be46e117db0370bbf7a69a45535d89cc6313079c5fbf573b7a47b35c6c888b499ab029910de98fd0f4989"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Dopaminergic Neurons",
      "id": "33bf5a667c04792d6dbea2f308ab342792bd66ea8986863564b45b8ad252462f5ea440b2c9f2f12b90b991b1a11c0291fe2dc4b4afcad8e9442d3950ed576f6b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Entorhinal Cortex",
      "id": "3b961d9d3bad880bcec73dbe82d95ca0bd9f339c6d087006350356c550e4dbb55acfa8c3376b1ebdacff8fafe1afdb1cabea7ea6f7ef77cb8142fba8a4010554"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Peripheral Nervous System",
      "id": "2acf48eee47597ed7ddfd515dfb36be47316a96eab23be32c772671645a86d53ddc3549eb65d6b079fa69e67080f36eec39bcfdcb8983ce613ea97e54103e940"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Receptors, Nicotinic",
      "id": "ab9ab8a42f27ea8b317e817b34a7ed7609808e3ccad71f0ce8685fa7b9e53fd847534ce7483452cc11f2166657f178e8e6804466c34019ef9674372b725b155d"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid",
      "id": "1810c6a03b02a2c9ede4030ea3c0036ea68c3d3a16a29622a07ce0bb0c24c5bf9b306066cdd71785548f5a4a735241fbdb3f671a0e2f1fdef9feb75d2951ea32"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Anesthetics",
      "id": "2480fc41215ae2bbb787f2a36e2ef724fe0b67db11767ae4596560e2b1f57f9d2515022c0ea35f8c91af69be8d8e8fdb5a3096b16c617e0ccf83ff933f0a9914"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Conotoxins",
      "id": "ee4e5ddcb7bfebdfc50f66b6b85fb514c14ed15068532db0f3f791f99941decdc4fa9e6fd258428e7d8c95b7d09377304468e6540eb0650fe4c3e5ac7328a51e"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Hippocampus",
      "id": "caff813aaa3f73ff030fa368884d30438c42f1f22aa2b372a08646bda846d5a6ee94d85bb4de2153aaa55ba41bd82a361353793ade6e39bccfe43c75f5a95750"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Lymphocytes",
      "id": "f674387b2ae6b99c3d0734359bff1bcd33330f771548132865eb726f1e1269c1589ead5aaf15257461d347c195ea1826df25822167d2acca7c38abfbd3404c04"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Neurons",
      "id": "130131072f276d163b9e361a4ca4814f1d254907d297db502ccb4f6e75dff10db1f2b384bb435c9b46e91310d585aea1db3108e00905a31bb1388ccda1f0c643"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "methyllycaconitine",
      "id": "a206e63249e698cd582378ad6f9731c7d949254405a5a71d42dcca57341f6df2b9e3daf878d48a7858472079773006edf34a0676c5a903e10a234f520b437ba5"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "pozanicline",
      "id": "707896cce25038a01453ddf83a1a873fd4d690d4ec13c587301e690f9548bbde1f9ac534ee5f4cf3b609bd050de91828a8232a6843f1be01ce5d6aa89be5f82e"
    },
    {
      "function": "Abundance",
      "namespace": "PUBCHEM",
      "name": "11964458",
      "id": "d276b4e6d5259e047066369347015c48ddcd9adf89b9683cbfbea35f31e8c6b17686c2154f2653ca4fa509a5a5c555089d8b8e047b1e2d335723c834589206e5"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "regulation of cation channel activity",
      "id": "43d5e99113f24f01591ef45d38a4ff8aa43d47907db0d43e90e1598068628a0e7e5a943c12c19f2d2788a26ad0576a73d6d2016608c0f4d65b79616df1edcfae"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "cognition",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "learning",
      "id": "24fec79fe31de63921d3028dd6ce5e335372d8d221877724830f05136d6c879daa7585768231b87272f0ebb8a7f6038f1aabb8785a626cca0c95b33018cc1633"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "memory",
      "id": "87795d00588bdf77d28229ad379d58f00922f6339902a803d0672cc15e669269f8fe50785b2851e1e82046f4e1e49920534ec68c0b6911bea5a1b838dbc999cd"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Cell Survival",
      "id": "abeaa000ab588015eac485dd605b78602795a7e237f3b097d8148a27fa3ebcc7a221d318d0399960d9f10cf194fbc9c29f41a2a8ed8c332b09f4b79680170b61"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Sensory Gating",
      "id": "5f2c32d2906e49c3e661c50d6fa4f59f85451f3c6c7813a585949097a5b5e511d6ca4f8d6f87035754a1c977c47b74f86495f6284e0eb58942a23d55222e5855"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Neuroprotection",
      "id": "4faae7cda7ea712ac9d9c27de14c6457cd84758cc7195c23f72e23fa92f07677fd6328b40deb0811b5e6fdda4375bc95095893a935493c67ad814bd89755e3b1"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA10",
          "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA9",
          "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04"
        }
      ],
      "id": "813dfa455035120e852362effac97d922ade188d55ccf012863580ac6683d5770d13b606106d943e50e01d520b693c44260a03c7672a4623a0cacc16493da80b"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA3",
          "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB4",
          "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"
        }
      ],
      "id": "c2a872c8548c02a60f1e06a8d384f798fe2e4d5c68bce0786ec4788ea98e9c3034227b18261bb492807e45a48591a802b06d3a9b5f81778205b8e4d57e2bf051"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA4",
          "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA5",
          "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        }
      ],
      "id": "7c58f988dbf28454f26bb34c9d3d5f875300fb3186f4fd94633f2c084178642a3431041c82ee2416f00135d010d084280a583a93249443c0ededa492743b44cf"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA4",
          "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA6",
          "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB3",
          "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"
        }
      ],
      "id": "9859cdd4d956a9580cdba768f15be6a1a1faea5d3618e7a30805255f7740707378046062e89e415ac18310fb09ab832c047d30e12af972c4ae71638af31c5fb0"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA4",
          "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        }
      ],
      "id": "d4fd90112c85c79fe7510d181fe801440ce05ef1193b78089fca9732d1e118ae19ab42d218393e25a7f515dceefd26f86d0465e72ea9ec47542be18ef8ca49c7"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA6",
          "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        }
      ],
      "id": "d75cef49f914e4b0306bfb8bc9d4f88e79e9241adbacbb9ad5ff45f0bc2d5180048d809eb80d86fa0f515ac9e838c919d49b3b3a460a6d1809c6dbabdb84ff78"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA6",
          "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB2",
          "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNB3",
          "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"
        }
      ],
      "id": "f70d21861807ba4cd7031f2e81c2e17c3a4bbf7f132a3e003338d35a149261f29542e3e52f058b453f31ce842f21b2b42e03ff0b231734328af6c65a63280561"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "CHRNA3",
      "id": "20791db7edbda906e807ddea89be4976f78cf09baf1278269333c84130a14109cfef906c562d00d6bd5579836b08cf90124f7f48067f34f7f621aa74703585e5"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "CHRNA5",
      "id": "e72fd07e99372e053ee4b566253c3881d5c3f27a1c8fd4422b57f5822075beaaed4f236be63d9885ecc8860ea8045b7dc482b0028677e7939e216d7d354115ea"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "CHRNB4",
      "id": "f969d5ec226a65fc34810ab44ad0a3b7267dd91ad8ed9d53da71b0f4f8f1ecf6b354ba95d4d6c5b7ee91266c032fc7e33d58e20dc73bb11108b2c082b394b269"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "CAMK2_complex",
      "id": "2c6d989e05bba1439ed18819e9d74c2d3a247c0c70287041ff8f1085c44c631acbd1c98b8726b0dc365e3ac3089319e14d3837f2225ff67307609b1bd1e4d8d3"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-2 beta-2 nAChR",
      "id": "caff8f0934cf82a8aa15dec31a055bd77c5926cfe3df0c9b4ea5f83f0b3b499de7b97617f1fc1ae9b5874b449125bf1ecf1db0043e5b7c5caa71ecd61bcdda4b"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-3 beta-2 nAChR",
      "id": "978f090b6df94e1da305071a7247b758036277306095f25ee56a9fdea0e01a8144f11111e9e8ba09998e3f6da8ade003a1ac3b80484e62091ed9bb7ae83bb877"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-3 beta-3 beta-4 nAChR",
      "id": "a81dc6465d21f2c4e7caf3c0d8d421e2b1704f81c6bf28a89559ff3e7d17fc2a68ceb287b33a628ac2b9f8a1a26481cbb41bdde270f96e9c4d1ed9e755f9d753"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-3 beta-4 nAChR",
      "id": "12c3fb53fe98b91af78875c0589072fd9938b21bfa9e2663a8118ae0c4207f9b67c464a248f92732405380555991c239af43ef36592b8e158f5ecf82f9087cdf"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-4 alpha-5 beta-2 nAChR",
      "id": "9d7733eea3ad5a5e8ad648ef612f7f663cd694a5b5b8d3b4f2bc1a032dfcdab810b617ad565cfd305daff93f4f03d21a7b4f29c0f97f5cbad88e34d9002f76f2"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-4 beta-2 nAChR",
      "id": "ec5179cd967d90750035c116468a0af9a0ef91ed915bfc394b1c3cc6ba722f9607198c01a6030a990c02b80c744ec0cc9e1cfa64e517d2afee33de99df3530e0"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-6 alpha-4 beta-2 beta-3 nAChR",
      "id": "fc114bffb37e57281465b23fbc9a5227b036d6a878b7739ebda7131ae3eaac2b43097045477da765ba93c7787215fbd5b7647ac7a5ce3fe10380d7f22d868076"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "alpha-6 beta-2 beta-3 nAChR",
      "id": "d5b5e75c6b99b669e394f4f4a401eade29869bfc0634efe3d7bb0e825db3b779c01e0ec6d6718557b4f31b8cac4479465716c231621323deddde67550fd1fc24"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHAT",
      "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA10",
      "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA2",
      "id": "019d1c092def2bddf48f48ad995d60d9628fb0125b814a5e643e6910d6eeac771b60993b4c3408eb54aa70f35c7ae8fe499737202541875d1f38277a8bb9b237"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA3",
      "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "variants": [
        {
          "kind": "frag",
          "start": 331,
          "stop": 600
        }
      ],
      "id": "c290dc7c55aaea79c93bf44a6a2aee24c4054d9a257e173aa2b3a7d8c8c584c247dcc2db3418c8f38aabedcb9ed0160f1ffca38e005660602458cef61ec0e966"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA5",
      "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA6",
      "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "variants": [
        {
          "kind": "frag",
          "start": 231,
          "stop": 255
        }
      ],
      "id": "128d9214b33a13b519a02da3896b0fac27173cd61858e8afb07e634bb38330de06007778b94e0389ee16ca373028a2eced3f97caa044cbedebb2522d1e4b61fd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "variants": [
        {
          "kind": "frag",
          "start": 262,
          "stop": 280
        }
      ],
      "id": "5e36fb0d2c702d40c5a3a7c1177ce25863b4feef4bcb610c84599eb53ab2520c03bf00e7b20b8da1fe7a6e04b4093d82f36ba76940d86918db3a8ef847ef5ebc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "variants": [
        {
          "kind": "frag",
          "start": 470,
          "stop": 490
        }
      ],
      "id": "1efe6081c046cc978d81f8263dbcb6475694ff60a4383ecfd598a09739cee94dfbad9fc82f36249aa2c720926c769e9cf002124ee2a32fac102f472b092c9b01"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA9",
      "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB2",
      "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB3",
      "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB4",
      "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "DNM1",
      "id": "fe99c2afca7fbd6b47fe79ac4c44597822cda051bfa9c74931df32a59806661ebed570d79128b095fccd0f2dd80af46e162744991435d7113d9a9c0854459494"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VSNL1",
      "id": "e0486a910d2a6edd1103f30adbad37c5ac2667a43b3f37481e6929b43c4aa528658575e467cf8b8eba2fbbc27a23271181ceba3bca8da658f1ed1a27d8de6e1b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "YWHAH",
      "id": "fc959d43e13021deb88a4f790f56621a46dbff8c907e260d9a545407cf4f7645cf36b820cd99c4110236a8760e1c0d4433d37cca5f02d241273918d0d36fcefa"
    },
    {
      "function": "Protein",
      "namespace": "HGNCGENEFAMILY",
      "name": "Cholinergic receptors muscarinic",
      "id": "bc4355d51c8dab82808ce004ae55c19edf51d387a57828854966a6340f3b344bfdc99f1e6c56624b645fd7994f14bb952a8d8607088690e787c1d934048706cc"
    },
    {
      "function": "Protein",
      "namespace": "HGNCGENEFAMILY",
      "name": "Cholinergic receptors nicotinic subunits",
      "id": "d55bebfe65f49c8e66d1ed0b491af0f01aba4b030a649599e59150e53ed4d3e4cd2199be8863b95c7033ab2185d8d7ea9203e5418faea9d7dcc86757b9bcf4dd"
    },
    {
      "function": "Protein",
      "namespace": "HGNCGENEFAMILY",
      "name": "Clathrin subunits",
      "id": "717ed31e96de950c1d153b77f6e596bb79d2de1c798242647571a921576d6e279944707fc6e5498b04ec5a18aa6709b84ea08cbb708e8a1e8fe2f9cefb0f1d27"
    },
    {
      "function": "Protein",
      "namespace": "HGNCGENEFAMILY",
      "name": "Tubulins",
      "id": "324eb02c65169e7a583a43ee128ed844b5c108fc4d0a4ae7ad0d5cc6db3c3da60b70719f5de9b87efc1f0e09bb8d753028201d1f815f971a39d6fa306086dce7"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "neurotoxicity",
      "id": "1f25791dbb09af20ea60156b4ab96950653396306bd4059d680a6baeb4a0872d1d483dc8a80de8c3be1b693c2254b41aad6b88fa1726ae383fe80d3069b3dd3b"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Attention Deficit Disorder with Hyperactivity",
      "id": "54b187d282fb0e425c6fb7ddacc52e6e6fb254ad3fbc758c2409a3439b3793675b958427d8395f3116e2cca91e8e8ede843c9d80e65904212282f94b7fbed12b"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Lung Neoplasms",
      "id": "d92e9bff009ed76caf4716b8e43be58be2ab9f8ccefeb4a114b2f09967cb7912baf173efea2afc5fc28674ede07d2eb6cf2f496570caa8af04c5ed0804983d6c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Memory, Episodic",
      "id": "1e3c1dc405e08e0a9a500a8f1a97ed80d71732d86f0816e51acb9caf5ac95cb217165824ff6133d61bd1a5ad2ecb08fdd2f4ac4911a5193c67e30e8ab003ffb8"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Plaque, Amyloid",
      "id": "888c33ecabc995942e605aace0106831b95c6e6d4eb99ee4ac4c1de25ff7c58c0cb67b5e941c2d3f3a399aada51a34de03850a43011389d2ab7dae07536cea30"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Smoking Cessation",
      "id": "297d269f2523b8bcac7b8d19fbac4cebe5e1f5feb69d02977efab3ce3a084e2412f41b77e3272973e1383f13343a7007e7b709b9c84e40bad5b206eb328bbf8f"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Attention",
      "id": "67735e2aaf2e17459a41794138aa7720fd27fb15a51cb7f34b74132b92accef7585efb2a338de3ca85bd2a5ae6bc4f7aac672d1a06b2e19c5e45400ba7b94036"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Craving",
      "id": "8de85da862b6cc27d0f4643dc7055a69f5070dac04a1edd8c34a36f4fb6540c477df493ea80b8b8c09b19009b305c407c4b1870858140e24ec2f3aab31ba63de"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Delusions",
      "id": "cd322d6f7c86cae1a3997c0bd58a460b404f6f50d1bd936e05dfaa2b58dc3701b70c23b50f9244edb3c42baf1c0239dec16d8f57c9daff7eb3b934e5ef592c34"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Depression",
      "id": "1db8d744eac9b5ac408852b1889bb0b09e0054ea091932f1aa44aeeab0ea1b3825912c55c72fb2d25d5848e77d62b1c6a1df2063a2f25ae03e5ca30085922799"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Hallucinations",
      "id": "ad73f79878286e99e48ad8b2ff196bd160666327c138014eae6150c76c71e650c37b2e6e083ba61dfda68dd41a788462fb101c654e6ad160cb434a2076b5df14"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Nausea",
      "id": "76613aad01556d20038f32be68dc0dee4ca1a032b70d7b64a967daf007cf535bce562835b50af6a482040811d773d93cdd8732eeb2aa137f19396665b213da79"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Nociception",
      "id": "711b886347e9a54d49cc1677229e898421dc351164134ea87beb8578c53f21555c68d7c79fa6a481da2da1b8204d0c1f04ea7d039aeb920a1f8645447f21c0f4"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Pain",
      "id": "7c892602ec0888a53b7e5325e40732d94a33e4074ea60461ff7fd223bd15bf9b1565c0b2069497dc15ce86e489f9ddf69baa3101578567cae0fb9f81dbaa8e1a"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Recurrence",
      "id": "2739617397124e3eabf53dcf25c77bb5bc0db2713082ba9fc88b177939c1139a694f9034b74aa513d1f4b8342b3e07ca7b08b27d25f90a5afe42f1778a9e4871"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Schizophrenia",
      "id": "574fcb4e3970e1cefa6d4d88a96a5c535f41ece9b53fe0a456e4f7aeb388900e1d66e72e024e1f50c0892640dc2faae2adb82b00a4c66c9aeec93db08dc4a136"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Vomiting",
      "id": "0997523c73935a3a0ed39198a04b8abd904fc14fba9168590d27722b6293c8810b1b808504dc1be4768657a34fe3a9429658035700a0200ec2397f6868a8481d"
    }
  ],
  "links": [
    {
      "line": 89,
      "relation": "increases",
      "evidence": "ACh is produced by the enzyme choline acetyltransferase and its actions are mediated through two types of acetylcholine receptors (AChRs) — the G protein-coupled muscarinic AChRs and the nicotinic AChRs (nAChRs).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 73,
      "target": 6,
      "key": "2661bf75bc2099780dcbc19b4836b190677144091535b2b499a9e1d5656568958312cd3aea8caf259b4205d303c02691e4effd1e50a009c37e6dd0ff85e188b3"
    },
    {
      "line": 179,
      "relation": "association",
      "evidence": "The acute effect of ACh consists of the fast opening (microsecond to millisecond range) of a cationic channel that is permeable to Na+, K+ and sometimes Ca2+ ions.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 6,
      "target": 47,
      "key": "9651c7d5d82def405913f8f13645821d10fa7eca4f5944e8a12204fc7cec223c1b43d47fd502e758f5ad23a2ea072cf04c714c6c948dbb96639bac91f5d2970c"
    },
    {
      "line": 90,
      "relation": "increases",
      "evidence": "ACh is produced by the enzyme choline acetyltransferase and its actions are mediated through two types of acetylcholine receptors (AChRs) — the G protein-coupled muscarinic AChRs and the nicotinic AChRs (nAChRs).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 92,
      "target": 6,
      "key": "8ab85b75bceafcaeacb1f90d0e131fdcc55443e2d650311ee3791e1f82526a5b479671553ce4a178fc86b1f85caeeefb681c7eb6768d9150a4a4b0cd6911605b"
    },
    {
      "line": 91,
      "relation": "increases",
      "evidence": "ACh is produced by the enzyme choline acetyltransferase and its actions are mediated through two types of acetylcholine receptors (AChRs) — the G protein-coupled muscarinic AChRs and the nicotinic AChRs (nAChRs).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 6,
      "key": "938b3b1ad6711687af3be47e175b0c29e1df2b1e4fefbe16939494cd9fd201b7495c023df0e72eaa86ce3f35fb01d11d9ff141666dc75d7232c8519915559775"
    },
    {
      "line": 161,
      "relation": "association",
      "evidence": "The nAChRs are ligand-gated ion channels that are present in both the PNS (at the skeletal neuromuscular junction and in the autonomic nervous system) and the CNS.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 93,
      "target": 36,
      "key": "6a57903e4e83c7d5aec49457bcbc2a742a3f0a7881ebf8075fb917e3f5d49ea8f36aa08acad309fa17368d9c95632b27bd8f6eb6ef6d17f16cdd89123f05f3c6"
    },
    {
      "line": 162,
      "relation": "association",
      "evidence": "The nAChRs are ligand-gated ion channels that are present in both the PNS (at the skeletal neuromuscular junction and in the autonomic nervous system) and the CNS.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 93,
      "target": 32,
      "key": "d50438b1873843fce567eca29661e0e965799f817faa330f57611c22f044cb1a120cdce608b1cd2c3a6b217e77f58fdd2b8842260e21ea0af8bb5702d414c6e2"
    },
    {
      "line": 169,
      "relation": "increases",
      "evidence": "Typically, activation of brain nAChRs results in enhanced release of various key neurotransmitters, including dopamine, serotonin, glutamate and GABA (gamma-aminobutyric acid).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 93,
      "target": 10,
      "key": "f413a33d84bdf726ecfb076714b841c37186d826ad54c63a174c49ec52b04de43912fad213af7f829d195e71dcbee182cd48adca3a79c559d2e7631a680a4e42"
    },
    {
      "line": 170,
      "relation": "increases",
      "evidence": "Typically, activation of brain nAChRs results in enhanced release of various key neurotransmitters, including dopamine, serotonin, glutamate and GABA (gamma-aminobutyric acid).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 93,
      "target": 20,
      "key": "b96f6b29ca9da5726bfe1b53be224663aa5532ee73ad8b551a811646c6493ad295ba6f3b683699ea43e89215968bc777668846356a7d46e10bf5f2eac2b31d09"
    },
    {
      "line": 171,
      "relation": "increases",
      "evidence": "Typically, activation of brain nAChRs results in enhanced release of various key neurotransmitters, including dopamine, serotonin, glutamate and GABA (gamma-aminobutyric acid).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 93,
      "target": 3,
      "key": "be8bb4ccc62a3c4dd788db82e52cb44af469c2840ccc8cf09428d63162de2f975ec52d12498bd5dc7aeb37729ef299a1ca41512b4a78df35e5ba6660e8a63e0f"
    },
    {
      "line": 172,
      "relation": "increases",
      "evidence": "Typically, activation of brain nAChRs results in enhanced release of various key neurotransmitters, including dopamine, serotonin, glutamate and GABA (gamma-aminobutyric acid).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 93,
      "target": 2,
      "key": "2731c9e6bb7679f03f2f75be0d03d310a181e570e5f121eb42ee77ae75a13cf744e02cdb2ce1ccb62767dfe45be361f5c73a654c403ca122945870b4ea00f2fd"
    },
    {
      "line": 204,
      "relation": "association",
      "evidence": "Cholesterol is known to be crucial to nAChR function, and it interacts within the transmembrane domain between TM1, TM3 and TM4 (ReF. 57).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 93,
      "target": 7,
      "key": "725b8c17ac9320c0707beb36b154ede4ed9e6016c0e3c0203a1d79ca57da8914db4a70a831788fcfb317b7489ba40ffc7b5c2db389e2348eb322ae0adc25dbf0"
    },
    {
      "line": 483,
      "relation": "regulates",
      "evidence": "nAChRs are known to control sensory gating, and studies investigating the role of nAChRs in schizophrenia have focused primarily on alpha7 nAChRs. Sensory-gating deficits in patients with schizophrenia174 have been linked to chromosome 15q14, proximal to the alpha7 locus175,176.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 93,
      "target": 52,
      "key": "65994695ae8090011e5fccc6365f554f73fe27cbb9ace39a7e0684565b72b4f8f62469bcde41eb53a58f4ef127009a16f7ea0f94eef045312267ae9d60854f7e"
    },
    {
      "relation": "hasVariant",
      "source": 81,
      "target": 82,
      "key": "0a49c1b719f1f7db672db84dbd987ded1a893d2104a1efe2d3280d4fd72d79601b2da7b05b99bb639b5842426a63e47f1a235a703cf6eaf6d88863b783814f94"
    },
    {
      "relation": "hasVariant",
      "source": 81,
      "target": 83,
      "key": "2dee3501691d53cc0046132cb068994487c2cd997e8ef6aa80e92a37e6563637ea44118daf611bb35a793f7a9b31628e446b2e99ce77d0c95a5de3892353f002"
    },
    {
      "relation": "hasVariant",
      "source": 81,
      "target": 84,
      "key": "4da833eade14ece096320de3189a05f638b5dc209dbc3c677abc8eb18cab326b108b9a17ce87d6a19b47ceb17bf89ac92c495c1c21c798163ac62ad5054a15fa"
    },
    {
      "line": 275,
      "relation": "positiveCorrelation",
      "evidence": "in the cerebral cortex, the massive reduction in nAChRs in Alzheimer’s disease128–130 involves predominantly the alpha4beta2 subtype, sparing the alpha7 subtype131. By contrast, in the hippocampus, a loss of alpha7 nAChRs seems to predominate and to correlate with the progressive loss of cognitive function132–136.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 81,
      "target": 48,
      "key": "c1fcf4c56c09c62588a15042c34129dc5d2d546a212fb1fcaad14675f0e627d78d4b3d3a809f510098a2498d6a71b8bf81190785124a89e5b42d099e11dcae31"
    },
    {
      "line": 312,
      "relation": "increases",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 48,
      "key": "8d623612354b1cda0ceef13249a8a6200dc5b386019099f10ae084debff12805fc5450acbe6713d7556caaf4f78ade6c19cd38b882ddace6f3306fc0ee580598"
    },
    {
      "line": 305,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 81,
      "target": 41,
      "key": "9368119f6013d6e245be007592a00d75859e6305cc0204eca7913dcfcc95275b4042ca8703394d0887319d6403b7abbefdd7047e1ff759ad6315aa603e8c4d32"
    },
    {
      "line": 307,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 81,
      "target": 50,
      "key": "8e35f68fb9773f65a3e0e56453845e177749a49f91290f2ab1491978aa3fa5eededdb331fd7c6c6ae87ef4b44d8c17ed2cc282f88e52cd0d077d32ee12004b4e"
    },
    {
      "line": 414,
      "relation": "decreases",
      "evidence": "By contrast, deleting the alpha7 nAChR subunit in a mouse model of Alzheimer’s disease that overexpresses a mutated form of the human amyloid precursor protein confers protection against memory loss and synaptic dysfunction, supporting a crucial role for alpha7 nAChR as a target288.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 50,
      "key": "95ad4907345e9b2d3f3f2f4a1882fc89f2cd0f884c02c2d531211b6c9bf7fcaceaeaa9cee894b73337f1caa6aa4d1632c798bfa18a16b94801ff1f337cadcd27"
    },
    {
      "line": 308,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 81,
      "target": 49,
      "key": "b42183be1606f94983c9fff29b58356506ebf0fcbda23aae057fb0ff62fa5cde2b27733d4fae9d9ef87d82251da6a91049d3e6cc8dffe597e6130182d23bca48"
    },
    {
      "line": 375,
      "relation": "association",
      "evidence": "The alpha7 nAChR has previously been implicated in the in vitro neuroprotective effects of nicotine, using PC12 cells151.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 81,
      "target": 53,
      "key": "e9b314a60f3c08598ab483b09fddfdd60fdf37f56b97aa6955099af2b26d8adf91c381a7e0b266a22d7f2ee53ac0c661ec5c07ae4dd7c4cc91b7732e6d2eb880"
    },
    {
      "line": 413,
      "relation": "decreases",
      "evidence": "By contrast, deleting the alpha7 nAChR subunit in a mouse model of Alzheimer’s disease that overexpresses a mutated form of the human amyloid precursor protein confers protection against memory loss and synaptic dysfunction, supporting a crucial role for alpha7 nAChR as a target288.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 81,
      "target": 53,
      "key": "3115375ffa132f9e42288b719e8bf98c7bec51bec7f70cb4c29344609ca1476330ab6d6e904d708a39b3e509f3893525a45aab743183d67c1b3ac93d074362d9"
    },
    {
      "line": 503,
      "relation": "association",
      "evidence": "in addition, a decrease in alpha7 nAChR density in the hippocampus of patients with schizophrenia has been reported177. Similarly, a low density of alpha7 nAChRs in inbred strains of mice is associated with poor gating178. Recently, the expression of a novel variant of alpha7 nAChR, CHRNA7-2 (cholinergic receptor, nicotinic, alpha7, variant 2), was found to be reduced below control levels in the prefrontal cortex of patients with schizophrenia179.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "Species": {
          "10090": true
        }
      },
      "source": 81,
      "target": 52,
      "key": "4a8e70bc393ec7e1d16ebc873af517f93d91f7473b3808f5463d6966dc66d6f70648d718c05e9f03edfa0d564b3530d5e737bb880a8b23fca757b44ff0f9773b"
    },
    {
      "line": 530,
      "relation": "association",
      "evidence": "However, the atypical antipsychotic drug clozapine normalizes auditory gating in DBA/2 mice — an effect which involves an alpha7 nAChR mechanism181.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 81,
      "target": 9,
      "key": "f5d1605202b7db69b212943a39ebcb926b7656a89f5baa146c4433f1b291dcbce1e659a54c5b82200214f6902a00203774b80e79b5822a5025ee128ba3bc681d"
    },
    {
      "line": 161,
      "relation": "association",
      "evidence": "The nAChRs are ligand-gated ion channels that are present in both the PNS (at the skeletal neuromuscular junction and in the autonomic nervous system) and the CNS.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 36,
      "target": 93,
      "key": "f285377fe9394d274dc9cb49d4487002cd46962d17b71c11fc4536fdbef50976e6d5537ae039f5c2ed40d597419e4feab7b9f403e5dac40376b07a13e32ad50f"
    },
    {
      "line": 162,
      "relation": "association",
      "evidence": "The nAChRs are ligand-gated ion channels that are present in both the PNS (at the skeletal neuromuscular junction and in the autonomic nervous system) and the CNS.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 32,
      "target": 93,
      "key": "8226456eb47fea9d6fa061e67ad36840a47f984413758a1ee18ac7963bd8b3c0645273e22834cd44c4831a82964b4e50e31b030831316b1f8745f6a9e6c9de0d"
    },
    {
      "line": 179,
      "relation": "association",
      "evidence": "The acute effect of ACh consists of the fast opening (microsecond to millisecond range) of a cationic channel that is permeable to Na+, K+ and sometimes Ca2+ ions.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 47,
      "target": 6,
      "key": "8a645906490c2808eb5cab162303b9b33f5fe44b6ddda72a7d9449b35d3d727c31d7b79bf62f45ed99e49e90dbaaf0ff1a549d17149d2be8072cb0dfd3b0d6c8"
    },
    {
      "line": 186,
      "relation": "increases",
      "evidence": "Chronic exposure to nicotine causes a striking increase, typically by twofold, in the total number of high-affinity receptors — a process termed upregulation8.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 15,
      "target": 93,
      "key": "51e08a86edf7cf6aac5fd2e3689a73fdd9ec6a0ba838042251040e9a9de013098af95036fe24ed9ef2297ab3032fd9b89f4bff7d5511564c92a22516b24df6e8"
    },
    {
      "line": 428,
      "relation": "increases",
      "evidence": "Regardless of the exact effect of Abeta1–42 on receptor activity, it does seem to block the activation by nicotine and, consistent with the cytoprotective nature of this interaction, amyloid deposition limits neuroprotection151. This phenomenon may explain at least part of the neurotoxicity that is associated with Abeta1–42 (ReF. 156).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 93,
      "key": "d675b17b9824a7ddc99892cc9d910923d110a61fbbbfbe0a4b795a4384e193587d4be6f8365cf386e8bbd93bc13074e59974f078c193c3086e029c272ab90610"
    },
    {
      "line": 289,
      "relation": "increases",
      "evidence": "early studies indicated that acute nicotine administration improved performance of patients with Alzheimer’s disease in cognitive tasks, whereas acute administration of the non-competitive (channel blocker) antagonist mecamylamine resulted in dose-dependent impairment of performance in a battery of cognitive tasks137–141",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 15,
      "target": 48,
      "key": "624335708d35c5a340a57c8e8d4cd206afbfb22f04eb810100326cd66c3b17c0ade2acc80c713c234e55acb5a4b2465e9ea96f4b88e0c05b54cae72571b4b8ae"
    },
    {
      "line": 376,
      "relation": "association",
      "evidence": "The alpha7 nAChR has previously been implicated in the in vitro neuroprotective effects of nicotine, using PC12 cells151.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 15,
      "target": 53,
      "key": "b57adfa40c4f9ec69f37e58d7ac0c0263584fc50b7d83d7c63ce6c242dab45b7fb4e345396fdde290657b8ade2cf24115b8b302be9cb9147d5a0138cb1af2e22"
    },
    {
      "line": 452,
      "relation": "decreases",
      "evidence": "Amyloid plaques form in the entorhinal cortex of patients with Alzheimer’s disease and this region, which connects the neocortex and the hippocampus, plays a crucial part in memory. it has been suggested that plaques in this region represent the lytic remnants of degenerated, Abeta1–42-burdened pyramidal neurons, and that amyloid internalization depends on alpha7 nAChR mediated Ca2+ entry162. Of interest, chronic nicotine treatment has been shown to reduce the plaque burden in animal models of Alzheimer’s disease123.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 15,
      "target": 101,
      "key": "7908f31c84ad1a508f006793d97f8e7b4acc8d341fc7d6e0c7013f4e370bd1d4f3663b410e252da087067a07e0ac9cd5b15b7b5b6f76991f1881c458f8c9f39f"
    },
    {
      "line": 520,
      "relation": "increases",
      "evidence": "Patients with schizophrenia174 and DBA/2 mouse models180,181 respond to nicotine administration with improved sensory gating, presumably through alpha7 nAChR activation182,183.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Schizophrenia": true
        }
      },
      "source": 15,
      "target": 52,
      "key": "5b7c0afa973e73412abf3d251b5608c18a244ce00fa37b29358e87de428432e921d7249e600d235ec2af8f2659335712ce3c81d39120869a454527b8ccf36490"
    },
    {
      "line": 613,
      "relation": "association",
      "evidence": "Moreover, nAChRs containing β4, α2 and α5 in the habenulo-interpeduncular systems are necessary for nicotine withdrawal in mice107",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 88,
      "key": "3bf29247cd5d54f144af36a47384a1bfbae8c6a6dedcb1d07f4c14d7dc838620924647be75e7713ff4fcf8ee6bbe209e8a96da66581b2baef8aef371a1c5a6bd"
    },
    {
      "line": 614,
      "relation": "association",
      "evidence": "Moreover, nAChRs containing β4, α2 and α5 in the habenulo-interpeduncular systems are necessary for nicotine withdrawal in mice107",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 75,
      "key": "4fe348e6bb380cf9593b948a1dd783dbfb9bac61c78ab3eabd37108413676dc75c3300cb1553d9bef78e685f05a1d0294436f61a39bf4f4e3fc0e7c617b77f34"
    },
    {
      "line": 615,
      "relation": "association",
      "evidence": "Moreover, nAChRs containing β4, α2 and α5 in the habenulo-interpeduncular systems are necessary for nicotine withdrawal in mice107",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 79,
      "key": "3292f6f4aeda6dc7271df17cb56836128bd13f5e5e0853c4c825e5c5017ea1cb7aca9f2a85d24b86e058b4f774efb96b921c959e6c36ba731cde3cfd770d6d97"
    },
    {
      "line": 699,
      "relation": "decreases",
      "evidence": "Also, α7- and non-α7-containing nicotinic receptors directly or indirectly (through GABAergic interneurons) modulate serotonin release in spinal cord slices230. However, the identity of the receptors that are responsible for the spinal control of nociception is currently unknown. in this process, the nicotine-induced antinociception seems to be mediated primarily by activation of calcium– calmodulin-dependent protein kinase 2, but this is not the case for supraspinal nociception control229.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 109,
      "key": "3cfeb2caa069a55bf579b8942da907a9717dcfeb94c396fa96f7697b115f6b047ecb9635b64f75b64851a38b509300972a02f441611821dffd5b5f8fb731c072"
    },
    {
      "line": 751,
      "relation": "regulates",
      "evidence": "Nicotine facilitates dopamine release by acting at both somatodendritic and presynaptic nAChRs on mesolimbic246,247 and nigrostriatal247 neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 15,
      "target": 10,
      "key": "f70fa92885b065329d40159858b83e9270df82b285124867402c8de5987dc58d2a59f4b389ad1e9ac48b9d9882ab6c9ed8a819a541b133bc7a7b6676f68f4144"
    },
    {
      "line": 191,
      "relation": "increases",
      "evidence": "Most neuronal nAChRs, including alpha4beta2 and alpha7, are potentiated by Ca2+ at millimolar concentrations50.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 81,
      "key": "7e5732162cbd2a1c7fbf3169e266d5b07a278c8d684f51d5059834fc33d2c4fcbc0b1369c33e4ba31e9eb864dd283a46e3b206e6971d627166e79356c19df3b1"
    },
    {
      "line": 192,
      "relation": "increases",
      "evidence": "Most neuronal nAChRs, including alpha4beta2 and alpha7, are potentiated by Ca2+ at millimolar concentrations50.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 1,
      "target": 70,
      "key": "1896ecc1aa81563cf5bd6596911112e5424b648ef733cfbc0c623a9769d3b5c1988aacac7debd62f2ffaac54b4188d3b229b351dfd9e383b49a72cf5725cbf17"
    },
    {
      "line": 198,
      "relation": "decreases",
      "evidence": "in parallel, a voltage-dependent inhibitory Zn2+-binding site has been identified within the beta2 subunit of the alpha4beta2 nAChR48.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 4,
      "target": 70,
      "key": "3d70bbb5fd87a7e59dd57f43ae5ebe26200bc470ce144e487480cdbd929ebd890a70980c0541a942a76b128fd1eb3bd27d292ca61816378d6d38c6934eaaa459"
    },
    {
      "line": 204,
      "relation": "association",
      "evidence": "Cholesterol is known to be crucial to nAChR function, and it interacts within the transmembrane domain between TM1, TM3 and TM4 (ReF. 57).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 93,
      "key": "ed1f21046394648ca7644cc3a331bb26f8609a9936ba680cbdf9a52241f6074b293b0cd8e86bcb1cdde8ba2a496a1658688b6178b007b42e29286115c66e337f"
    },
    {
      "line": 211,
      "relation": "decreases",
      "evidence": "General anaesthetics are small hydrophobic compounds that typically allosterically inhibit nAChRs by binding to specific residues within small cavities of the TMD61,62.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 39,
      "target": 93,
      "key": "be45d6d0a3484cd067cf28194dff045d08f0e80a2361824cb8759f4d0ea4880f79399bc60174edc25a33fbfd276104a47cfc5406cf310c8803f30c6a1cf6269a"
    },
    {
      "line": 221,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 82,
      "target": 26,
      "key": "8fc65d970f367e00376d220474ead42aa0270fb1944b2cbeb6e661d2f2221fa1e7c6fdd0bd9168a0738cd5882c5a6b8040c5f98b56950a16fb70e0551c6b025f"
    },
    {
      "line": 225,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 82,
      "target": 46,
      "key": "bd39a75ce64b36eb798c22c49eb8369bfcd3e032ef332192e779e5685097142ab109f0357ccdfd6695cecef8cc015a97a6741de658aae4c63991dc5e5cae3eef"
    },
    {
      "line": 221,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 26,
      "target": 82,
      "key": "58d435636a25c09dcb37ffb4e120e85a978a5309469562b9d41760a8ac4c37cc12e2ab81d773a782a48603299e3258a33d9f3ec8239d76f799f7c0c32579884b"
    },
    {
      "line": 222,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 26,
      "target": 83,
      "key": "805017b155d2b61a44d333ca34487991f0f566dfcf351ee8003f7fe2d748f8e3e504a5598f19175cdd136f9c94edd899c8a93f286ba478d0a95b5a8c4f21b2e8"
    },
    {
      "line": 223,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 26,
      "target": 84,
      "key": "0de206a53f078589ff9946572cbcc78834ca7abe4fa6b4a030e45b59865ba1f16b5f296f312cbeb3d9c8100976063b8f82ab719848c1fd334d72eee1553ab56c"
    },
    {
      "line": 222,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 83,
      "target": 26,
      "key": "b8089b5e084bec46d9bf5f293d7b138ffdf6957443a6d86d543347e0d00f444ad9ed1e23299fad5266c8e123bb81f8dc546b8ee91c0b66f19b4fa0b98a5ef839"
    },
    {
      "line": 226,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 83,
      "target": 46,
      "key": "1d5b81d3d2fbc6921713573a12f409dee0a4e3f3310b3bcdfc48e84b69a5af6d186e9646ba11616a07637f714ba1a9abdc30baa8a3bb2e4c5bba50fa47ce1e66"
    },
    {
      "line": 223,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 84,
      "target": 26,
      "key": "2bb4f6c18920ce814a1e7c5d616ca57ec51810fd55b5afa3d568c0956d41c351e3583ae2c0742629fb43cb81c8a0a8e15548efb59476ff3c086f6ea42ae44abc"
    },
    {
      "line": 227,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 84,
      "target": 46,
      "key": "67c6e44efd7653e8a05d517f1a2fee15d5acfa60a7bc394eb4c4d7530278f44863f39dd051e0e72676e57703eb7303505d9d4952cf71b2d4a95ec134a8f62cb2"
    },
    {
      "line": 225,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 46,
      "target": 82,
      "key": "df8f05f6f73bbd1a657a8a7f1399f872d049f6650317a2137335e0f7cd09ec2cc24b39c46b80badfe3d56d81155f982a5c560ffcd004c17538cd944956e82c66"
    },
    {
      "line": 226,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 46,
      "target": 83,
      "key": "d7120823e3eb01f07d0e5596b73b82826891fcddccc5461e3da4ec6a08fc989df33012d742d92c81636bdd49deaa3e24be1267e3dc2cabddc374cba4a97dd274"
    },
    {
      "line": 227,
      "relation": "association",
      "evidence": "The binding site on alpha7 nAChRs63,64 for the positive allosteric modulators PNu-120596 and lY-2087101, has been tentatively identified within the transmembrane domain. it comprises five amino acids within TM1, TM2 and TM4 which, when mutated, substantially reduce the potentiation of alpah7 nAChRs by allosteric modulators",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 46,
      "target": 84,
      "key": "2574c51167ef836d41e2f068111ccd18d3452a5e25faabe3e4339b9470e1c1e114882d0994d0ad553dccaf3b9b328bd13f3f83f974e1d4599dd3cb434d16e224"
    },
    {
      "line": 237,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 78,
      "target": 91,
      "key": "ac8bcfb8799ae1af671fc82f2e64811d519b42a6f0ce7858b18d03b0eff4e19c2d432b64072db2bca46a9b5306f35e69380637eea68c253b1b02ccf10a323942"
    },
    {
      "line": 238,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 78,
      "target": 90,
      "key": "1050dc893ef9036cf9b57955b24c3a0041416b734055dc212a1400c93b5f56baeca18fedf1545c3088dde17d0719670899b3bc8ea0a73eb494263dc9dd187dee"
    },
    {
      "relation": "hasVariant",
      "source": 77,
      "target": 78,
      "key": "786c9142f00f453c3fab26d785df86f324e9008758c6fd5f46baa05fff90e56bc0eb995b11c33ec9dff6091d799d7763c9cc8125391d1569537139ac815fe291"
    },
    {
      "line": 683,
      "relation": "increases",
      "evidence": "in α4- and β2-knockout mice, the responses of raphe neurons to nicotine is abolished, together with nicotine-elicited antinociception228, and α4-hypersensitive knock-in mice show nicotine hypersensitivity in the supraspinal control (hot-plate assay), but not in the spinal control (tail flick assay)229.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 77,
      "target": 15,
      "key": "fb02512d8cdeb0bb80ceafa9218125cd62fed047064b24bf9d6dd04cd697012fd419217a3c07d25b3925a5429b3a4bdb110693ac2ba0e395f7d9a8453b43931f"
    },
    {
      "line": 237,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 91,
      "target": 78,
      "key": "90db3515b03bfc209481cda7636e59d35aa5429ede864332ade81195fc53f515d7685d896028026a558886bd446c1202099053ed15b5bce78188d527e16be23c"
    },
    {
      "line": 238,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 90,
      "target": 78,
      "key": "412438142e2502d148b53567b42556fcfdfceeefb5dc23d6f2ecdcd6f146125fdc3a14cbeaac8e3a33be5770f7ffc8c58021779bc40bd9e0a541b012060fd7d5"
    },
    {
      "line": 239,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 86,
      "target": 95,
      "key": "ba7fa141a2601b27a3643e229d6afaee8a1f40638e77a680f526ac6cfa3bbc170a9713ac10a1367dab40fe3bd69fe976766450b495b27e8ca8f491928f206754"
    },
    {
      "line": 240,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 86,
      "target": 89,
      "key": "61e6e78afb7cf65d2b8e2a565a3d8523729476ba932060011d5364fe6977e76b7d9beae541018faa0430cb813071a44c0c16efeeff69d03a6118424b6749ab43"
    },
    {
      "line": 241,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 86,
      "target": 94,
      "key": "1bc2d03e80fba63dfd3d5799698f11da28dde5483fba2aa403a51157286a3c3b7613db1bfc15ca4efaf1c84ea6f4cbb3c406af49b3d24cf7e3e49e90dbb940ce"
    },
    {
      "line": 684,
      "relation": "increases",
      "evidence": "in α4- and β2-knockout mice, the responses of raphe neurons to nicotine is abolished, together with nicotine-elicited antinociception228, and α4-hypersensitive knock-in mice show nicotine hypersensitivity in the supraspinal control (hot-plate assay), but not in the spinal control (tail flick assay)229.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 86,
      "target": 15,
      "key": "40710148d98c34b05c4e460e40311fdc67f26dcd2358559cf2c17b67bda86032f0e1ad3066da41bfdebba7b14f8d7367e43adf8e182bfff453925a74473c22f9"
    },
    {
      "line": 239,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 95,
      "target": 86,
      "key": "1c3308df384e69fb7ca90cc48c1091f8a5bdd49684dd35079730eb1164c55fbe10b92de34c8fdbaaa5281d2abd605617a08e839cb5adc3a2ce963004fa1fab63"
    },
    {
      "line": 240,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 89,
      "target": 86,
      "key": "02b044b1687e40a5130d53e252fdd6fbe032abf690392f23608dc4523a25b983f8ac1b9d97a30eb628bd155668b58938d3d074f4b4caa964a1680764ee684707"
    },
    {
      "line": 241,
      "relation": "association",
      "evidence": "The cytoplasmic domain of the alpha4 nAChR subunit binds the scaffold protein 14-3-3η and the Ca2+ sensor visinin-like protein 1 (ReF. 69), and the beta2 subunit interacts with several cytoskeletal proteins, such as tubulin, dynamin and clathrin, and with G protein systems that are involved in intracellular signalling pathways70.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 94,
      "target": 86,
      "key": "180a8d90e49e8a5087f08cd82754fc78132faa69ca1ca2ee2a2b29ca8220133600f8f1933a0cbea40450432dc67e3ce65e3c9a1dc796287cab27ec510c2551af"
    },
    {
      "line": 252,
      "relation": "decreases",
      "evidence": "Alzheimer’s disease is characterized by progressive cognitive decline, accompanied by a loss of neurons and synapses — especially cholinergic synapses — in the basal forebrain, cerebral cortex and hippocampus126 and by a substantial reduction in both muscarinic and nicotinic AChR expression127.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Forebrain": true,
          "Cerebral Cortex": true
        }
      },
      "source": 97,
      "target": 48,
      "key": "36ef65067463ef4570adcabaaf09afc4628bb051bcd7315371403dd13b18730433d155432edbba78226feb2aa4f0258ff1f7b1275e8041dd4c5d0ebe502ae4d5"
    },
    {
      "line": 253,
      "relation": "decreases",
      "evidence": "Alzheimer’s disease is characterized by progressive cognitive decline, accompanied by a loss of neurons and synapses — especially cholinergic synapses — in the basal forebrain, cerebral cortex and hippocampus126 and by a substantial reduction in both muscarinic and nicotinic AChR expression127.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Forebrain": true,
          "Cerebral Cortex": true
        }
      },
      "source": 97,
      "target": 43,
      "key": "f3943ea97991659406bff6a4fd47d71be8ff055be8fc8a87a1baeb222001033b845ca77cf1dbdc570cc186c8c0217354169ce9b058fd790e5d4314868eb3957f"
    },
    {
      "line": 254,
      "relation": "decreases",
      "evidence": "Alzheimer’s disease is characterized by progressive cognitive decline, accompanied by a loss of neurons and synapses — especially cholinergic synapses — in the basal forebrain, cerebral cortex and hippocampus126 and by a substantial reduction in both muscarinic and nicotinic AChR expression127.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Forebrain": true,
          "Cerebral Cortex": true
        }
      },
      "source": 97,
      "target": 92,
      "key": "0f6ba6a3f179659ee91ffa2b01739aac3183c79d351113bb03a119f91b61f5a7dcb50967e5c8e35d56faed220251597b41802cc2388ebcd7b18780b8c13749f6"
    },
    {
      "line": 255,
      "relation": "decreases",
      "evidence": "Alzheimer’s disease is characterized by progressive cognitive decline, accompanied by a loss of neurons and synapses — especially cholinergic synapses — in the basal forebrain, cerebral cortex and hippocampus126 and by a substantial reduction in both muscarinic and nicotinic AChR expression127.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Forebrain": true,
          "Cerebral Cortex": true
        }
      },
      "source": 97,
      "target": 93,
      "key": "ff311d9e2aa5e1b8813721eadc3c16bb0f96a5454cf9517f9ce54e9731db2a271a63ee94abe1138ed1aa3e5cf12d0f07eccd6397025a08bed804a0277974029f"
    },
    {
      "line": 268,
      "relation": "decreases",
      "evidence": "in the cerebral cortex, the massive reduction in nAChRs in Alzheimer’s disease128–130 involves predominantly the alpha4beta2 subtype, sparing the alpha7 subtype131. By contrast, in the hippocampus, a loss of alpha7 nAChRs seems to predominate and to correlate with the progressive loss of cognitive function132–136.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 97,
      "target": 70,
      "key": "f95052b47dfd10136a55bf62107e2f90ff8fb5277f61d3a9c7ce09bd53679a504e003841e466b5b6cf4ce5609af774c14c64ec357eb119fd64d424afe019a8f8"
    },
    {
      "line": 366,
      "relation": "decreases",
      "evidence": "Similarly, MeM-3454 improved the ‘quality of episodic secondary memory’ score, which is a measure of episodic memory. As for episodic memory, working memory is impaired in Alzheimer’s disease. MeM-3454 significantly improved the quality of working memory score in patients with Alzheimer’s disease in Phase i trials. in a Phase ii trial, the quality of working memory scores were also improved by MeM-3454, as was the ADAS–cog (Alzheimer’s disease assessment scale–cognitive subscale) score.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 97,
      "target": 100,
      "key": "6fa9ad1e6ac871dbe631ab342d3cb2caa0f57262ab5b877be501e4ebf8ffd220fa6a21f6b50a8f7258348cb64ea1e711e3edc88bc64d505d8619650dcdfa1c38"
    },
    {
      "line": 445,
      "relation": "increases",
      "evidence": "Amyloid plaques form in the entorhinal cortex of patients with Alzheimer’s disease and this region, which connects the neocortex and the hippocampus, plays a crucial part in memory. it has been suggested that plaques in this region represent the lytic remnants of degenerated, Abeta1–42-burdened pyramidal neurons, and that amyloid internalization depends on alpha7 nAChR mediated Ca2+ entry162. Of interest, chronic nicotine treatment has been shown to reduce the plaque burden in animal models of Alzheimer’s disease123.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Entorhinal Cortex": true
        }
      },
      "source": 97,
      "target": 101,
      "key": "6134678570785e7b8c6b32452ad2c36c31eb589bb658eb38502b5c70e2f362860c03aa25f11ba1ceba303a0b73d08f70b9fe7d9f8f46c3b87f7894805d0b3a49"
    },
    {
      "line": 275,
      "relation": "positiveCorrelation",
      "evidence": "in the cerebral cortex, the massive reduction in nAChRs in Alzheimer’s disease128–130 involves predominantly the alpha4beta2 subtype, sparing the alpha7 subtype131. By contrast, in the hippocampus, a loss of alpha7 nAChRs seems to predominate and to correlate with the progressive loss of cognitive function132–136.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 48,
      "target": 81,
      "key": "2662f269972058b23fa42371c7064664e2e702fea9d9fb767bc0007816bee1dfca508e4ba9ae397eb0862a823c0f6c0cf411a89feb9bc1ebf31fffba5edb794f"
    },
    {
      "line": 474,
      "relation": "association",
      "evidence": "in addition to the obvious symptoms of hallucinations and delusions, patients with schizophrenia frequently suffer from cognitive symptoms, such as the inability to focus attention173.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 48,
      "target": 112,
      "key": "702c4405c15d43c9cd256f73664b3d7edcc8ee6d07ca565eed24fc09a26cfadd22bae6262ca37c1596b6566cad1917737b0fa8d56089346612ae3afe51e7e9d0"
    },
    {
      "line": 290,
      "relation": "decreases",
      "evidence": "early studies indicated that acute nicotine administration improved performance of patients with Alzheimer’s disease in cognitive tasks, whereas acute administration of the non-competitive (channel blocker) antagonist mecamylamine resulted in dose-dependent impairment of performance in a battery of cognitive tasks137–141",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 5,
      "target": 48,
      "key": "fcead8f9e730f9a2f06bd9d1f106aa1f3abe33b968aae9ef9229432a6caaee8aecd525b946ca7b3403b28b22adc712bdba89c152326ac27bb0a7216a84694475"
    },
    {
      "line": 305,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 41,
      "target": 81,
      "key": "2da2dce40f1047392320f459e6de1d67578ed13e9680de5a3ef4844eb5c32364310a2d5f7cec1414faae5747fd356ba9d0083c494e8197e279e63da35852eda0"
    },
    {
      "line": 306,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 41,
      "target": 50,
      "key": "98eb747587866b5c5ed11b04ecd3ded167044c3a34b9d798319220c61a17bbb30fd4117ba6fe3e7ffaf1e8a7dcad0ce9b5afee81a4ba9897b1309726af83e9c7"
    },
    {
      "line": 306,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 50,
      "target": 41,
      "key": "682e4ee3c2255cb6ddbe402c2aff7135b1a6c187cec931edfa0bb62b3489783da68a91ae397372a5b744d2ef9e0fe5c884b709e077bfa84092869c45e5784c22"
    },
    {
      "line": 307,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 50,
      "target": 81,
      "key": "c16d976b485ad62e935b1126dfe823fc614285feab3e7aa2889bd76eee355bfdd9269244deef449aa725510c8310b90191cc8b9538c4686078fbcdf2c6de6d0c"
    },
    {
      "line": 446,
      "relation": "association",
      "evidence": "Amyloid plaques form in the entorhinal cortex of patients with Alzheimer’s disease and this region, which connects the neocortex and the hippocampus, plays a crucial part in memory. it has been suggested that plaques in this region represent the lytic remnants of degenerated, Abeta1–42-burdened pyramidal neurons, and that amyloid internalization depends on alpha7 nAChR mediated Ca2+ entry162. Of interest, chronic nicotine treatment has been shown to reduce the plaque burden in animal models of Alzheimer’s disease123.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Entorhinal Cortex": true
        }
      },
      "source": 50,
      "target": 35,
      "key": "a9bdec516642f0bb8e0d02d9372f51c58a5aada344694317744e0dd5fc344d5e2e062f382ace3e2c20e678d9f9aaa0cc5f6e341dadf5b002c23e2a214faa70dc"
    },
    {
      "line": 308,
      "relation": "association",
      "evidence": "First, there is a high level of expression of alpha7 nAChRs in the hippocampus, a region that is known to be involved in memory formation. Second, gene knockout and antisense studies have shown a role for alpha7 nAChRs in learning and memory144–146, and specifically in attention and working–episodic memory147,148. Third, pharmacological studies have shown that a range of structurally diverse alpha7 nAChR-selective agonists or positive allosteric modulators improve the cognitive deficits that are associated with Alzheimer’s disease.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 49,
      "target": 81,
      "key": "b42138c0329ab24a8fe9ee4ee43f2d88155a73111bcdb6723d1db1a431dfb317faf3c337c4dc8a1ba5e8a628ab882f6853d9eab245c4cbd6f79b3248935ce279"
    },
    {
      "line": 323,
      "relation": "increases",
      "evidence": "As expected, AR-R17779 — a selective partial alpha7 nAChR agonist — improved scopolamine-elicited deficits in social recognition, and the 24-hour memory retention interval in unimpaired animals. Repeated doses of AR-R17779 enhanced long-term learning and attenuated working-memory deficits in rats.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 31,
      "target": 49,
      "key": "75528795c105b6d72b2025c885ecc424cf72ec8f16964147f83baed3691a5d54df1669b7c94a85931409dc6c4c64da03f1f3be84a72b874bcdc67dfb86694f71"
    },
    {
      "line": 324,
      "relation": "increases",
      "evidence": "As expected, AR-R17779 — a selective partial alpha7 nAChR agonist — improved scopolamine-elicited deficits in social recognition, and the 24-hour memory retention interval in unimpaired animals. Repeated doses of AR-R17779 enhanced long-term learning and attenuated working-memory deficits in rats.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 31,
      "target": 50,
      "key": "9d1e097fa8b862f4a275fe5912e82e67aacaba50bb97281e71b41b4f444d77a18ee260c7befb21c7b469cd94787d9b8ad132cdbe5ce9746c87d87a1935b4be3a"
    },
    {
      "line": 325,
      "relation": "decreases",
      "evidence": "As expected, AR-R17779 — a selective partial alpha7 nAChR agonist — improved scopolamine-elicited deficits in social recognition, and the 24-hour memory retention interval in unimpaired animals. Repeated doses of AR-R17779 enhanced long-term learning and attenuated working-memory deficits in rats.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 31,
      "target": 19,
      "key": "14d359de8df5bf9533a2863c1621d465c75e2dec9cd3f9603fc14a4bf15bb95e3e7c90cbe1fdee70b09ff6bf628cea3d20bdd5c70e75b5c260f55dce45e7f411"
    },
    {
      "line": 335,
      "relation": "increases",
      "evidence": "Two partial agonists of alpha7 nAChRs, GTS-21 (also a strong alpha4beta2 antagonist) and MeM-3454 (also a strong 5-hydroxytryptamine type 3 receptor (5HT3) antagonist)149 (TABLe 1), further showed a procognitive action and, in preclinical studies, MeM-3454 enhanced episodic, spatial and working memory.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 48,
      "key": "7c531d0ba904f1d0777183952f4e236259789fc38f5d6e2c60669869ade9ab09c204972cd44831ed2a8171bd7193dae619c7cb360579654a1d385dfc80e823d2"
    },
    {
      "line": 353,
      "relation": "increases",
      "evidence": "in a small Phase i clinical trial, GTS-21 improved episodic secondary memory tasks, including word recall, and picture and word recognition1",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 100,
      "key": "92888eb5c5d4488ee708e38f3d16c8bff20b0d651b582d8071aa8975ff9df0895484d4fa84af2136d18f497e3d8d4de8d2b4bbe389e1fc96fd630f67f8801066"
    },
    {
      "line": 398,
      "relation": "increases",
      "evidence": "As with nicotine, the weak alpha7 nAChR agonist GTS-21 is neuroprotective, specifically protecting against Abeta1–42-elicited neurotoxicity154. This effect is probably due to small, protracted increases in receptor-mediated Ca2+ influx. importantly, high concentrations of GTS-21 reduced cell survival, underlining the possible risk of over-stimulation152",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 53,
      "key": "449ef246ed586f84e485cfe35da6edd6335f8a603880427348d1b5ac7d5e693de65dc25c9bf6f0de65066efba391791d145bf964ff5cc51fbfb23a7d0e90201e"
    },
    {
      "line": 400,
      "relation": "decreases",
      "evidence": "As with nicotine, the weak alpha7 nAChR agonist GTS-21 is neuroprotective, specifically protecting against Abeta1–42-elicited neurotoxicity154. This effect is probably due to small, protracted increases in receptor-mediated Ca2+ influx. importantly, high concentrations of GTS-21 reduced cell survival, underlining the possible risk of over-stimulation152",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 27,
      "target": 0,
      "key": "bfbe822b555a58c586bdb154b7bcfe221c6f25661aeb378b56d20d7ea4692828adebcbb068ebaa3c41f683d54decd0602ae3dcf9dceca4d5e688251e5e4df5df"
    },
    {
      "line": 401,
      "relation": "decreases",
      "evidence": "As with nicotine, the weak alpha7 nAChR agonist GTS-21 is neuroprotective, specifically protecting against Abeta1–42-elicited neurotoxicity154. This effect is probably due to small, protracted increases in receptor-mediated Ca2+ influx. importantly, high concentrations of GTS-21 reduced cell survival, underlining the possible risk of over-stimulation152",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 51,
      "key": "91693cd4bf01c700ac62f124af558689ca8b9725860f4ba5ab4c8bf35708d4f3bb6bb1d05cc4c918a9b6f0dff303fab03e06a03a8eb948e0819431394690a609"
    },
    {
      "line": 562,
      "relation": "increases",
      "evidence": "GTS-21, one of a series of compounds derived from anabaseine, an alkaloid found in marine worms, is a partial agonist of alpha7 nAChRs that improves memory-related behaviours in various paradigms and normalizes auditory gating186. it is the leading clinical candidate in the field of alpha7 nAChRs.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 52,
      "key": "a0afbf66f40dae42c0efd9c63b39bdeb91355cce1355df000e9f1c57e0c3b45336e5e6626486daca2a349ee032ad1b301aece28d19342ae58fc12661cde3dc9b"
    },
    {
      "line": 572,
      "relation": "increases",
      "evidence": "initially evaluated in normal subjects, GTS-21 was found to significantly improve attention and memory. in a second Phase i trial187, GTS-21 normalized P50 auditory gating in patients with schizophrenia.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 52,
      "key": "68c83e29ad8a446ae30e0655a96ee13b3745494333bdb60104176ffb52d14f156c64d7c295a60528fe88d0f563ab2273b784325ecb9e517426e23bf3e8774803"
    },
    {
      "line": 563,
      "relation": "increases",
      "evidence": "GTS-21, one of a series of compounds derived from anabaseine, an alkaloid found in marine worms, is a partial agonist of alpha7 nAChRs that improves memory-related behaviours in various paradigms and normalizes auditory gating186. it is the leading clinical candidate in the field of alpha7 nAChRs.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 27,
      "target": 81,
      "key": "8b64f35f987eb20b4dd7cfc5fa9ac93b1d2ae21eb638a233143f18808084d6141c620f0b48e3fa3826fc7b20de9e560b988516307e6799c1118442b72c8b60b3"
    },
    {
      "line": 570,
      "relation": "increases",
      "evidence": "initially evaluated in normal subjects, GTS-21 was found to significantly improve attention and memory. in a second Phase i trial187, GTS-21 normalized P50 auditory gating in patients with schizophrenia.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 50,
      "key": "317046ad21c09e3ce90102679aa47ddae352b21672f2272370b98947c4065e90021a455c1481f25d104bd360c56deb2bda0873ab4abe2b532e7c07f1d473e6ff"
    },
    {
      "line": 571,
      "relation": "increases",
      "evidence": "initially evaluated in normal subjects, GTS-21 was found to significantly improve attention and memory. in a second Phase i trial187, GTS-21 normalized P50 auditory gating in patients with schizophrenia.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 27,
      "target": 103,
      "key": "ac9063f986cec87db5b8dd006582f50e6e7dd53285684f0672d54a2ef182af0193560cdbde9be7a99b32207de140982c289fcface01f67ba47de0934fa27ebdd"
    },
    {
      "line": 337,
      "relation": "increases",
      "evidence": "Two partial agonists of alpha7 nAChRs, GTS-21 (also a strong alpha4beta2 antagonist) and MeM-3454 (also a strong 5-hydroxytryptamine type 3 receptor (5HT3) antagonist)149 (TABLe 1), further showed a procognitive action and, in preclinical studies, MeM-3454 enhanced episodic, spatial and working memory.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 25,
      "target": 48,
      "key": "5f80cefb4e25822adf021ea3a249f74f453a80ef14c1edfecdc92d642e3e913bb6469dfc74e2a64be4e23f07114364ee647fcc0600aeced156193dc3a3033532"
    },
    {
      "line": 338,
      "relation": "increases",
      "evidence": "Two partial agonists of alpha7 nAChRs, GTS-21 (also a strong alpha4beta2 antagonist) and MeM-3454 (also a strong 5-hydroxytryptamine type 3 receptor (5HT3) antagonist)149 (TABLe 1), further showed a procognitive action and, in preclinical studies, MeM-3454 enhanced episodic, spatial and working memory.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 25,
      "target": 50,
      "key": "447a294928b2aac75d552acedf77278c133213b4833ba9423eb4406dc9947f0dbfeb3841a577b15eda8ad6a063cc42c3f725c28aee4dc08a7536dbded64bd21e"
    },
    {
      "line": 367,
      "relation": "increases",
      "evidence": "Similarly, MeM-3454 improved the ‘quality of episodic secondary memory’ score, which is a measure of episodic memory. As for episodic memory, working memory is impaired in Alzheimer’s disease. MeM-3454 significantly improved the quality of working memory score in patients with Alzheimer’s disease in Phase i trials. in a Phase ii trial, the quality of working memory scores were also improved by MeM-3454, as was the ADAS–cog (Alzheimer’s disease assessment scale–cognitive subscale) score.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 25,
      "target": 100,
      "key": "c081eacbf66ebfe36bd11eed14fb2836400a23e3aa3664835ec1529f94d1a7f07ffad6f35541ae86be88fd3ff5fff2165ffa8c727860232919be0c753ee3f435"
    },
    {
      "line": 346,
      "relation": "decreases",
      "evidence": "The procognitive effect of MeM-3454 on episodic memory was completely blocked by the alpha7-specific antagonist methyllycaconitine, establishing that the efficacy of MeM-3454 can be attributed to alpha7 nAChR binding.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 44,
      "target": 25,
      "key": "0ce8a30de18c871c843217d4d1806359e27902d6a86a51aa77c4ac7d38d90bc250a88f6ae5c7df5c6e016355235bdd33c321fd41a39ffcdebb9713689887ea78"
    },
    {
      "line": 375,
      "relation": "association",
      "evidence": "The alpha7 nAChR has previously been implicated in the in vitro neuroprotective effects of nicotine, using PC12 cells151.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 53,
      "target": 81,
      "key": "37ec9d51207827294b31f98b232c2d2086c66ef5a5b61009392193b610757367dc38676de85302121bef8bfa6810b5424afd5714e741c31a26f5002a85de7308"
    },
    {
      "line": 376,
      "relation": "association",
      "evidence": "The alpha7 nAChR has previously been implicated in the in vitro neuroprotective effects of nicotine, using PC12 cells151.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 53,
      "target": 15,
      "key": "17b6f812091d48bdaa94b25bd170c781ed09627cbaf3a5dea6ee6ac7ef1d1d40b7abfad4b6f9ad12a7f94a02dad7e4cd671665f8919e67090c41e2e288efb60d"
    },
    {
      "line": 386,
      "relation": "increases",
      "evidence": "Choline, like nicotine, can protect neural cells from cytotoxicity that is induced by growth factor deprivation152 or exposure to the glutamate analogue AMPA (alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid)153.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 8,
      "target": 53,
      "key": "0bfc9c399c1cf28263fb5b30a21bab9357d90c4bab354451a66b26bbce6ab8110f92d62815686e407b14367c0f42dc46dce2d025a52e57cc0a3fa5ad61874215"
    },
    {
      "line": 387,
      "relation": "decreases",
      "evidence": "Choline, like nicotine, can protect neural cells from cytotoxicity that is induced by growth factor deprivation152 or exposure to the glutamate analogue AMPA (alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid)153.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 8,
      "target": 38,
      "key": "1623927e360f8cb75fe3d3a34a0b3d9214e7217b0f0d5de3925b488761eb25f63e0b66890952cc58f67446cd1c413e8dd6479bcefed01f80329f5fd1da9e83f0"
    },
    {
      "line": 388,
      "relation": "increases",
      "evidence": "Choline, like nicotine, can protect neural cells from cytotoxicity that is induced by growth factor deprivation152 or exposure to the glutamate analogue AMPA (alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid)153.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 38,
      "target": 96,
      "key": "30754edfcdcc7e1f44bee8bf7f25152a467d82f238ff79f879d964e28d82157ef1cc68c556bb3a3584e27e29bb0302bf46f4ad9e02d52200d13a4866d1bdf336"
    },
    {
      "line": 399,
      "relation": "increases",
      "evidence": "As with nicotine, the weak alpha7 nAChR agonist GTS-21 is neuroprotective, specifically protecting against Abeta1–42-elicited neurotoxicity154. This effect is probably due to small, protracted increases in receptor-mediated Ca2+ influx. importantly, high concentrations of GTS-21 reduced cell survival, underlining the possible risk of over-stimulation152",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 96,
      "key": "97274d68109b97853c718463f97f7cbd27097a3598ecab2b9bbdb8816c5321c70804a78b318ed3c924fcafec0381749fbdf06592e7a9eecad48e5985ea5b3b28"
    },
    {
      "line": 430,
      "relation": "increases",
      "evidence": "Regardless of the exact effect of Abeta1–42 on receptor activity, it does seem to block the activation by nicotine and, consistent with the cytoprotective nature of this interaction, amyloid deposition limits neuroprotection151. This phenomenon may explain at least part of the neurotoxicity that is associated with Abeta1–42 (ReF. 156).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 96,
      "key": "e86684138e54772007d39a0e5e0a855f7f39da16cb85dd7b185d491b0c8473a625df22880d47b3bdb83249a8526617a4dca89d563794a02224498e86c31a85a8"
    },
    {
      "line": 427,
      "relation": "decreases",
      "evidence": "Regardless of the exact effect of Abeta1–42 on receptor activity, it does seem to block the activation by nicotine and, consistent with the cytoprotective nature of this interaction, amyloid deposition limits neuroprotection151. This phenomenon may explain at least part of the neurotoxicity that is associated with Abeta1–42 (ReF. 156).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 15,
      "key": "0f253152913f9801ef85280f2689d3b7e8d2e56e727f7f95db2ce58139092477b49d2655639c94fb6b1781c6db21e10bb4de71fbf2cbd32e5654f30cc686e938"
    },
    {
      "line": 429,
      "relation": "decreases",
      "evidence": "Regardless of the exact effect of Abeta1–42 on receptor activity, it does seem to block the activation by nicotine and, consistent with the cytoprotective nature of this interaction, amyloid deposition limits neuroprotection151. This phenomenon may explain at least part of the neurotoxicity that is associated with Abeta1–42 (ReF. 156).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 53,
      "key": "a5e9f48d17b1c11af4df5e78ae1f1780bd72b739381fdbee2f937a3d435874b75f5bc182ee46423c4ccec84a49d0fbc83f164d91782d54654535e03883ad5104"
    },
    {
      "line": 446,
      "relation": "association",
      "evidence": "Amyloid plaques form in the entorhinal cortex of patients with Alzheimer’s disease and this region, which connects the neocortex and the hippocampus, plays a crucial part in memory. it has been suggested that plaques in this region represent the lytic remnants of degenerated, Abeta1–42-burdened pyramidal neurons, and that amyloid internalization depends on alpha7 nAChR mediated Ca2+ entry162. Of interest, chronic nicotine treatment has been shown to reduce the plaque burden in animal models of Alzheimer’s disease123.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Entorhinal Cortex": true
        }
      },
      "source": 35,
      "target": 50,
      "key": "e39cd9d90591f836b3abb01e9577285f314a6bf18d4f0a7993bc30719fc6105304cd1d8dd4e8e217ff9a99c1b2ee130c1185b76208dedcfece344553c833de5e"
    },
    {
      "line": 463,
      "relation": "association",
      "evidence": "ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 29,
      "target": 98,
      "key": "01a1e92cde5e2bb591398374267439a785791206f9141b82a084b93c43cef103137271a6439c46f20f4e1c229f5e602154bb575bfff4fdf5081485438f4624f3"
    },
    {
      "line": 463,
      "relation": "association",
      "evidence": "ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 98,
      "target": 29,
      "key": "3ab93cc992852d0d0666260936e4add28149d2aa9930e272e8026bacef51ab7c4358585d7a31e39dd27edb7ec1a97c64b1479e0355fd6a3602db40632f636592"
    },
    {
      "line": 465,
      "relation": "association",
      "evidence": "ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 98,
      "target": 45,
      "key": "2dc4b183c02bcb7f9bb4b8ef5a22823139a7a4df8e9d2f0d8318326dd0bfdf72a9629476a01e8c99a60bfc8f218638f57076dbf7e099d0eb3d86b14b4799575c"
    },
    {
      "line": 465,
      "relation": "association",
      "evidence": "ABT-418, discussed above, has also been found to be active in a limited human trial in attention deficit hyperactivity disorder (ADHD)171. A second compound, ABT-089, which is a partial agonist at alpha4beta2 nAChRs, was also efficacious in ADHD172",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 45,
      "target": 98,
      "key": "753e301fb21a345dd6283f51553b8a44857e5972437512c6d71a8ab385127cd3fb77d4abf500e6888d5b9997364aa03535341c82c6a8d77c0c3848d1a9fb2137"
    },
    {
      "line": 472,
      "relation": "association",
      "evidence": "in addition to the obvious symptoms of hallucinations and delusions, patients with schizophrenia frequently suffer from cognitive symptoms, such as the inability to focus attention173.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 112,
      "target": 107,
      "key": "471fa616a7ffd74847e1b5dd73c766e01666a74f5ce8ac051211ebfe87ce159708f0c69ffbf6a74787d1fd90fa9ac3f4e4d54793037a2f67c1e01386fb890794"
    },
    {
      "line": 473,
      "relation": "association",
      "evidence": "in addition to the obvious symptoms of hallucinations and delusions, patients with schizophrenia frequently suffer from cognitive symptoms, such as the inability to focus attention173.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 112,
      "target": 105,
      "key": "f3f9689cf87daeb0f8575ea07a25c238d356bd55bc4cc5c83649a98ddd2064d60ac76b4de1a217e53194ee5b07fa1d3e252117747550e6a2f8bf7b6941434994"
    },
    {
      "line": 474,
      "relation": "association",
      "evidence": "in addition to the obvious symptoms of hallucinations and delusions, patients with schizophrenia frequently suffer from cognitive symptoms, such as the inability to focus attention173.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 112,
      "target": 48,
      "key": "ec61eb0b89262188e07ff5fbd9aa877b6501bec970aa253b248d32fbd8873f9a530bdd5b9ab6bee2b634a382cd0457a07aeb0caf72dbcf7e43fb41bfb7ad5ce7"
    },
    {
      "line": 484,
      "relation": "association",
      "evidence": "nAChRs are known to control sensory gating, and studies investigating the role of nAChRs in schizophrenia have focused primarily on alpha7 nAChRs. Sensory-gating deficits in patients with schizophrenia174 have been linked to chromosome 15q14, proximal to the alpha7 locus175,176.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 112,
      "target": 52,
      "key": "2d17696e6f7bc0873ee202167b59089ea732eaa7ab963d4b288b98a894324f8ab69e2b9e133c1701e6424ff9fcd79017e57480604473ce414d01ab54d9bb6085"
    },
    {
      "line": 497,
      "relation": "decreases",
      "evidence": "in addition, a decrease in alpha7 nAChR density in the hippocampus of patients with schizophrenia has been reported177. Similarly, a low density of alpha7 nAChRs in inbred strains of mice is associated with poor gating178. Recently, the expression of a novel variant of alpha7 nAChR, CHRNA7-2 (cholinergic receptor, nicotinic, alpha7, variant 2), was found to be reduced below control levels in the prefrontal cortex of patients with schizophrenia179.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "source": 112,
      "target": 81,
      "key": "43a822b312b124720ff2a0ac6589c5cd79dec59ee7cddfe08c5f6a619304a1332c01bee449b1f68b5ef550590078a8f1ce2186395814db6c056ebf3fdaac845f"
    },
    {
      "line": 472,
      "relation": "association",
      "evidence": "in addition to the obvious symptoms of hallucinations and delusions, patients with schizophrenia frequently suffer from cognitive symptoms, such as the inability to focus attention173.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 107,
      "target": 112,
      "key": "f662d5008b04ede61a1b12c168cbf729bf8e95ab194a3bf95c57484044384104ed3385e0221edbe69bb1849063d7ac4a7f8bbc05c89b55f6232ae7ee535caf5f"
    },
    {
      "line": 473,
      "relation": "association",
      "evidence": "in addition to the obvious symptoms of hallucinations and delusions, patients with schizophrenia frequently suffer from cognitive symptoms, such as the inability to focus attention173.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 105,
      "target": 112,
      "key": "3a9faab656923dff085fc94d9a1d60cc9e30a40f991b75c70809e3ebf64f82e29d850d80899d4b3171d565a22e275db53e26282cb1190a1d138e1a6d56ea580c"
    },
    {
      "line": 484,
      "relation": "association",
      "evidence": "nAChRs are known to control sensory gating, and studies investigating the role of nAChRs in schizophrenia have focused primarily on alpha7 nAChRs. Sensory-gating deficits in patients with schizophrenia174 have been linked to chromosome 15q14, proximal to the alpha7 locus175,176.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 52,
      "target": 112,
      "key": "2f9cc01be92f495e7250f96efc939387533fcfdfa02f4d7cf998c2d3e63646b16357e2bbecf71c86fe5cf3b5581d1753833ee7a8ea14db5c9843284214a3c056"
    },
    {
      "line": 503,
      "relation": "association",
      "evidence": "in addition, a decrease in alpha7 nAChR density in the hippocampus of patients with schizophrenia has been reported177. Similarly, a low density of alpha7 nAChRs in inbred strains of mice is associated with poor gating178. Recently, the expression of a novel variant of alpha7 nAChR, CHRNA7-2 (cholinergic receptor, nicotinic, alpha7, variant 2), was found to be reduced below control levels in the prefrontal cortex of patients with schizophrenia179.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "Species": {
          "10090": true
        }
      },
      "source": 52,
      "target": 81,
      "key": "8e760e60a4b5037933c661272932f11e4864be04e1b375af790412183da53618148872b647eff1fdbf0279c959dabc61f33969309df431efef719d6f8f3a595e"
    },
    {
      "line": 529,
      "relation": "increases",
      "evidence": "However, the atypical antipsychotic drug clozapine normalizes auditory gating in DBA/2 mice — an effect which involves an alpha7 nAChR mechanism181.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 9,
      "target": 52,
      "key": "ff29ac01a1daaedfe519021bd4da3bdab0d9c9c492126d6a27de6a808498dcbecfe17f7187e69014213bf74e96cf104d171f9ecb2e474b11d6abdbb85c8e1266"
    },
    {
      "line": 530,
      "relation": "association",
      "evidence": "However, the atypical antipsychotic drug clozapine normalizes auditory gating in DBA/2 mice — an effect which involves an alpha7 nAChR mechanism181.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 9,
      "target": 81,
      "key": "8226874b260dccbc7bcb229cc3899ace77baf212b14467577e871f38e91510d55d4d4755f1555317a7052d2e4e5b79d12692ddd63633ab61d3d6ccdcddae8fee"
    },
    {
      "line": 538,
      "relation": "regulates",
      "evidence": "Two compounds that are currently in clinical use might have direct effects on the alpha7 nAChR. The anticholinesterase inhibitor galantamine has modulatory effects on alpha7 nAChR and was reportedly beneficial for patients with schizophrenia in a case study184",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 12,
      "target": 81,
      "key": "53c5889b24635906bcae2c37a0a16d548206de1b30dfc80e475c90a4a8e1dc129bd31c20fdd18b8b5d36854f9fbd6a11c2c95e047086c2d2af9ad23c0d172f2e"
    },
    {
      "line": 539,
      "relation": "decreases",
      "evidence": "Two compounds that are currently in clinical use might have direct effects on the alpha7 nAChR. The anticholinesterase inhibitor galantamine has modulatory effects on alpha7 nAChR and was reportedly beneficial for patients with schizophrenia in a case study184",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 12,
      "target": 112,
      "key": "41cfee24f1bdbf7e3ad336203f8bd580184f81dbc96797149d9c4e6cab69457e2e076155aa948909dc825248777e2ac8e5d01826452f2d9bbcd0f8c5c0ad084c"
    },
    {
      "line": 549,
      "relation": "increases",
      "evidence": "Similarly, topisetron, a 5HT3 antagonist marketed outside the united States as an anti-nausea drug, also has efficacy as an alpha7 nAChR agonist and increases the inhibition of P50 auditory gating in schizophrenia185.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Schizophrenia": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 22,
      "target": 81,
      "key": "2b17b568e2e4d219b845d1cedcc2a34c6ba43bcaf7db5f21cf9ec896ca6e190719f066bb8833964af81eed9482dfb19d9906818803c8f15e1c47349a8a7d4925"
    },
    {
      "line": 550,
      "relation": "decreases",
      "evidence": "Similarly, topisetron, a 5HT3 antagonist marketed outside the united States as an anti-nausea drug, also has efficacy as an alpha7 nAChR agonist and increases the inhibition of P50 auditory gating in schizophrenia185.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Schizophrenia": true
        }
      },
      "source": 22,
      "target": 52,
      "key": "6cdaa8e1aa2edd0e85c485ce24a275317dda5198df7b56a51de958b31fe81d7509965514e9b73828c1e4e6aad5a46e8ddc9ee5a5e104a33a929d2c137e08cb74"
    },
    {
      "line": 581,
      "relation": "decreases",
      "evidence": "Nicotine self administration is also reduced in rats by dihydro-beta erythroidine (DHbetae), a selective alpha4beta2 antagonist199. in this context, partial agonists may substitute for the desired effects of nicotine and antagonize its reinforcing properties163,200.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 33,
      "target": 15,
      "key": "3d613c35818dccb8b8a9f47c20400b49ea9402ba43e620b068a9070976da11d15e64a955ee30f9b581cbd1d5ea711f7b36f48a729e9745116631060eada40a4f"
    },
    {
      "line": 582,
      "relation": "decreases",
      "evidence": "Nicotine self administration is also reduced in rats by dihydro-beta erythroidine (DHbetae), a selective alpha4beta2 antagonist199. in this context, partial agonists may substitute for the desired effects of nicotine and antagonize its reinforcing properties163,200.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 33,
      "target": 70,
      "key": "04f2aff3226cf1cae712cc8f461c96d6ade4add53add7a8dce207381b2a2dc018f86db3a9391310fb02fb4472f7e3b8595e735896ad4761e3b2a6b3ac6df6a15"
    },
    {
      "line": 589,
      "relation": "increases",
      "evidence": "varenicline (Chantix/Champix; Pfizer), the most recently approved drug for smoking cessation which is now on the market, is a partial agonist at alpha4beta2 nAChRs, and a full agonist at alpha7 nAChRs (ReF. 200).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 24,
      "target": 102,
      "key": "7e5f8b53e5218aab840bc32f9a333ebf11c782b3d8f732645c26c727bb3aa9f61656309a9244406bc899f16a41fa34a1f5347893cab052651b0e8d089b920c4b"
    },
    {
      "line": 590,
      "relation": "increases",
      "evidence": "varenicline (Chantix/Champix; Pfizer), the most recently approved drug for smoking cessation which is now on the market, is a partial agonist at alpha4beta2 nAChRs, and a full agonist at alpha7 nAChRs (ReF. 200).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 24,
      "target": 70,
      "key": "84e04564fd5f820ae4525d7190200ed2e2d86c1f9ca0adef61a0deeeee850ad814eca5d45114c575b4d38e7123e8ae35452e6e941d179ec29407451ca1cb1da3"
    },
    {
      "line": 591,
      "relation": "increases",
      "evidence": "varenicline (Chantix/Champix; Pfizer), the most recently approved drug for smoking cessation which is now on the market, is a partial agonist at alpha4beta2 nAChRs, and a full agonist at alpha7 nAChRs (ReF. 200).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 24,
      "target": 81,
      "key": "25bc0fbf1fa5c0d69adf73f70509c1ab2459ce43438f3e5f1af52e3298a58a5e028f0aaaa54ed2ea59fc74a278d2b66b0f620536b278192f594fb424c71e1630"
    },
    {
      "line": 603,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 34,
      "target": 57,
      "key": "fedaef650b94ce70cc0ac58a1309932854211cc2e53a32987018f71d7b3db3a59ae3fd69f039c76527757d7aab812c70579bd5e3d7ada2039f52266fa8f0ceb2"
    },
    {
      "line": 604,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 34,
      "target": 60,
      "key": "ff745b685ccec3b6f09bd4da6415478ce1a18a6515366caf44dcf4523a88fb8fc60ea9f94a6a7eeed489fd2f410afa37a8ff2e676f18721575e19cafcc5cc347"
    },
    {
      "line": 605,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 34,
      "target": 59,
      "key": "401efe47a0189b7f258338b5885a01c130c32f62180dbd866e93cf52031630371ec840d02415d029fbd24396823638c2a894f48ada428b04edd1db56b1ad0764"
    },
    {
      "line": 606,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 34,
      "target": 58,
      "key": "90ab65760be00c635d670e05d5ca91d275271119ac11e2c5f646b20c611299ffd62917a353c049ff7b6a317183f9d4081e4b03c6610e901dcd384c855a00793f"
    },
    {
      "line": 607,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 34,
      "target": 56,
      "key": "fafc8d6c301ba1a50cfcf304e007781a494834fc5f91fa6a63d93ac33d18f2f5a759fa62d94a94079d5f3229e8e8417f9aec0ea8f65e35d789825154073e4ea1"
    },
    {
      "relation": "hasComponent",
      "source": 57,
      "target": 77,
      "key": "442921253e6d113712ff3a5f1701dfddbeda3085ad3cd02ed07b1647dc2263cc3a336ecb441513331a32b5c70ef92e92b880baaf776a1d67a69f3d0e3bc56ebb"
    },
    {
      "relation": "hasComponent",
      "source": 57,
      "target": 80,
      "key": "ba522adb715eefef29c29808029a313d91b5d642a2639e8f6dcb9b0d7738903766fa27b26aef12ed8b07c05e704ddbbf8b430266b69a808d32c0fb7af9a0a42e"
    },
    {
      "relation": "hasComponent",
      "source": 57,
      "target": 86,
      "key": "a4378935184c8899f0ef7d54dc00f6f8890ad2afdcedeed92a924d5b29233baf7b515c181c4715c909868e4cc56f374b03ac7887a9e3084da7385a41ac7f1e2c"
    },
    {
      "relation": "hasComponent",
      "source": 57,
      "target": 87,
      "key": "780a22ecf48e84ee0b8914e1a3ffcc5947e223f49a17b5a928350c2a524da80b2688811385a1af161db771c4457100eb27d41949953f57c9d1cc761eaa3a0f60"
    },
    {
      "line": 603,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 57,
      "target": 34,
      "key": "26c850804d915bed79c5a93a5bf0463c881165e9eb0d669578cd02f69d3a24ba3c21d8debf3d83ec351628ca259496b251b0fe94741355f1293e56a8d4246d8e"
    },
    {
      "relation": "hasComponent",
      "source": 60,
      "target": 80,
      "key": "e2209ce6cd0def78891c81ac924d348a973639c7394c5a68585cb78db4cfe0b793538fa47cdcd262a7a1858de4696f46cf377dd42eb87e2dfb3195ade24c580b"
    },
    {
      "relation": "hasComponent",
      "source": 60,
      "target": 86,
      "key": "523413dec60b926715be07148e539d3b8044f1e768861687a2ab1cf486940ba13ec9c2812a82534f5733bc3de2e36ace05215524caaedf987759c0fed7320aea"
    },
    {
      "relation": "hasComponent",
      "source": 60,
      "target": 87,
      "key": "e0c68ed0176439f3e776053ba4713da4e7623d7128aa4c68f622ae5e21bd22d36a7561486203109cfa8ec7f6eead3bddd686d9550b48b15da289b05d94eb458a"
    },
    {
      "line": 604,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 60,
      "target": 34,
      "key": "cc86218b1b6a690c44df54d43e2d2411b0a16ee97fcebb431d09249c5efd8e468638d9a211568849d7f2385d16a05a421c9dcf8c2accc84a1989c6e5230dc2ed"
    },
    {
      "relation": "hasComponent",
      "source": 59,
      "target": 80,
      "key": "a4aa8287c7dc2899df275926d608d1ba9fbd47fb3792e0968d2a680e909946f2a9d5655db620b95129967b75f323413b5035f76dbeaa7b452fbe1066b08789f8"
    },
    {
      "relation": "hasComponent",
      "source": 59,
      "target": 86,
      "key": "354bacc76fc7bbdbe40458422e568536ad6ab2fb791244a5b2dd39334919beeda8ad3d96f766f31507eb76b3e0c28d536a6cdff4bf5bada00bc490760a5c2999"
    },
    {
      "line": 605,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 59,
      "target": 34,
      "key": "c1606480bc019eebde790120a0886b65fec0517e8fd32b178b12c49ace97ee1c23e7faa655116b173bd772921ae0e4e56d317ccf7f7cfa6366e84bccada2c1c5"
    },
    {
      "relation": "hasComponent",
      "source": 58,
      "target": 77,
      "key": "4e1a057c746665f5f9a1ef5f7cb55cca4a846183d1fdf51fb946be04dc68922d6707cba1f308a3f8bed826faa7a7ac091cfdcaa785ad11e3f1103f87ff75228a"
    },
    {
      "relation": "hasComponent",
      "source": 58,
      "target": 86,
      "key": "aae43c9e88eb8c7018e403f5882f818acbbde1d8580bc5ef238d29f1995e5adf24d59c3651561e1cfd059750d237b43e16aed54e029890a7d56185667945ae96"
    },
    {
      "line": 606,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 58,
      "target": 34,
      "key": "c57cf306f9b017f086f47b4a99a7b1e60c31744b27ba97851a48d6101be220346c1e813ee23cdb2cf31d70979d7dc65dac870b94fea505861a36320751c213d5"
    },
    {
      "relation": "hasComponent",
      "source": 56,
      "target": 77,
      "key": "9037a08bb098ed51d8e726bc9a9fade95c301ed7dcc29100ac46049e8472f24810335bdbcafe8ff99cf90e4509a6c90ac9a540db2e9c26a7df36e4beea6f2428"
    },
    {
      "relation": "hasComponent",
      "source": 56,
      "target": 79,
      "key": "2bd5516ab430ae75c7d6ab03d2c5e7118f8b0c92b39b3d773bada395328e6ca4b273d9f48edc40009a82fc14d51d96b4ab650acd44177a9f4b35bf9a870b6234"
    },
    {
      "relation": "hasComponent",
      "source": 56,
      "target": 86,
      "key": "c593787de1671f86ef4dd183cffd6dc847ab1a46af9613a373a3e2619aeb215c93590b42b12caa143c374a4a5e101e6bed2f27bd8b3c4fe013746f794db51c61"
    },
    {
      "line": 607,
      "relation": "association",
      "evidence": "For example, as discussed above, at least five functional nAChR subtypes have been identified in dopaminergic terminals in the striatum: α4α6β2β3, α6β2β3 and α6β2, which have the highest sensitivity to nicotine, and α4β2 and α4α5β2, which are more numerous than the α6-containing subtypes, yet with lower affinity for nicotine105,106,204.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 56,
      "target": 34,
      "key": "28bf34cc0769e582d0ef865513faff5c90dea4aa98f9a49f6ba58525b6fef6872ed4fcfcfc1640a78ae841448b155b4be5ad2e43d5353faa4b8fe6207aad34a7"
    },
    {
      "line": 615,
      "relation": "association",
      "evidence": "Moreover, nAChRs containing β4, α2 and α5 in the habenulo-interpeduncular systems are necessary for nicotine withdrawal in mice107",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 79,
      "target": 15,
      "key": "c607e874c6610012df7aa28c89f1a7dc8ab88daf394d9f1b9ce9eff3859c2e90af8487559fc1cc5b0cb07dbcff4e7b4f17faaa93ed29d184d6703f5f707fe4c9"
    },
    {
      "line": 613,
      "relation": "association",
      "evidence": "Moreover, nAChRs containing β4, α2 and α5 in the habenulo-interpeduncular systems are necessary for nicotine withdrawal in mice107",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 88,
      "target": 15,
      "key": "72b22f366cf421764cdee8573e286d1aee3f847ed39b20ed24d98c81aeb8b8fc49f8620e91b592de118478cf19ff5027cfb8d18866be85388efd57aee9702768"
    },
    {
      "line": 633,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 88,
      "target": 104,
      "key": "201271e28054ff4a9df225226de579bd5515cc2f0bb479d2420d00e6c50e48999f74762d7d7cc8c993bc4ce3900f5c89c7d0119d6ffe5b7fbf65a77eaa91000d"
    },
    {
      "line": 635,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 88,
      "target": 111,
      "key": "de9e30d2028b230a0c46a1a0a661a69844f28ec58f182df30d45a131483b2a9321bd886bc8681c1565a658dc48d4dc97ba3a1d0971b6dba319fbb98dccae893a"
    },
    {
      "line": 614,
      "relation": "association",
      "evidence": "Moreover, nAChRs containing β4, α2 and α5 in the habenulo-interpeduncular systems are necessary for nicotine withdrawal in mice107",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 75,
      "target": 15,
      "key": "4c38f86024615dc70fe71b1eb807d9411c7b4fe939c22bafff463b0a20b404dd3fa2f2709ff1f2cde6ebc9a5a3aafc0989fa4675ed6e19fdb6364ca816272c1f"
    },
    {
      "line": 621,
      "relation": "association",
      "evidence": "interestingly, three independent studies have mapped susceptibility loci for lung cancer at nAChR genes: CHRNA5, CHRNA3 and CHRNB4 (ReFS 205–207).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 99,
      "target": 62,
      "key": "fee3eb7a08448b98b2f2b91374b7c6c746989f5b63017bcab8cc6d5497920b89bd9303466cd84735810ef991250f386c5949688ec87e5347b618dee756553fe3"
    },
    {
      "line": 622,
      "relation": "association",
      "evidence": "interestingly, three independent studies have mapped susceptibility loci for lung cancer at nAChR genes: CHRNA5, CHRNA3 and CHRNB4 (ReFS 205–207).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 99,
      "target": 61,
      "key": "007af17013ff8ea16c03b822eb8b2d3320bb4eda93e4f1f2fc1df357d812326ee321142e1a33bfcf6a8c2f8828ad0a577c0c137a6b78c3af3c09f2694cd0eaf4"
    },
    {
      "line": 623,
      "relation": "association",
      "evidence": "interestingly, three independent studies have mapped susceptibility loci for lung cancer at nAChR genes: CHRNA5, CHRNA3 and CHRNB4 (ReFS 205–207).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 99,
      "target": 63,
      "key": "69460df1a472622818538b4a3871bebbe5994245cd62c9c82542b2df25de895f0dd44f9acb0c11c118e7eba50f8b22badcfc8ae930819a20e1f699da47a6273d"
    },
    {
      "line": 621,
      "relation": "association",
      "evidence": "interestingly, three independent studies have mapped susceptibility loci for lung cancer at nAChR genes: CHRNA5, CHRNA3 and CHRNB4 (ReFS 205–207).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 62,
      "target": 99,
      "key": "d83b3b83bdffbb78cf295db0696856f7df63a3b640d356e3486515de0c3f98ff836ecbf1a7d8894c8d534b47a34a50e0d7bedd3ca7425611cf0fa1e88fa1688a"
    },
    {
      "line": 622,
      "relation": "association",
      "evidence": "interestingly, three independent studies have mapped susceptibility loci for lung cancer at nAChR genes: CHRNA5, CHRNA3 and CHRNB4 (ReFS 205–207).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 61,
      "target": 99,
      "key": "2e7088643a358fe01d48814dedf3690572b3412f7108881627edb90e044118e06a4f1a01e23ca4f619b483516582e27f099494f7c0a8451e50abdd9478b94a03"
    },
    {
      "line": 623,
      "relation": "association",
      "evidence": "interestingly, three independent studies have mapped susceptibility loci for lung cancer at nAChR genes: CHRNA5, CHRNA3 and CHRNB4 (ReFS 205–207).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 63,
      "target": 99,
      "key": "ea41da514404d36c68b9d2dce1f9dd06bb3f3a01c725b5a5c7b1229a573d91a2c591c503b0c3360162ec95765f45d09489a3aa0a1751e8175970d95037e755d3"
    },
    {
      "line": 632,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 76,
      "target": 104,
      "key": "62ff22a5a9562563da10856cb91750c315676d62f0f95eb31e296a8089ccb16e7a9cf406fb079311dc91a6efe4818af24e45bdf9894fb22d64800570b2b9b637"
    },
    {
      "line": 634,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 76,
      "target": 111,
      "key": "6943242e3128ef4553d51a7b03dc4f45f44808ea3af3bdbaf884b061b91764fa33cee2e0ba9f3b08c0cc67915305551ca47a504e1811aa658cbe8c88b76774f6"
    },
    {
      "line": 632,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 104,
      "target": 76,
      "key": "878b44069c8553722253f2ad812b138fedde1552b73d8cd3ec52ebbab06e939085738aec4e61bb7c59e957f2cb6cc2711fdb6135443716406d1f2d8725cbd1b6"
    },
    {
      "line": 633,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 104,
      "target": 88,
      "key": "0d6b48a3c8dc8d52b4358b7dc9b85d3882d1abb953c1bdf67d70c66a145b3572a2c753b01eb712746efcb2388df1859951efee56189659dffdf2096d90752ab0"
    },
    {
      "line": 634,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 111,
      "target": 76,
      "key": "c5b7f3e568062b1d22af31bd6b82ff191e9a1c8ceaa9ee50fe71199bb4f570d1bce9649f5f5670bb9cbfda6e3afbfbef6c737178bf602bb8c08c04cda7074c47"
    },
    {
      "line": 635,
      "relation": "association",
      "evidence": "β4 deletion abolishes withdrawal signs in the mouse208, and α3 and β4 are also present in the PNS, supporting the view that they might be directly involved in craving and relapse — an area that is largely unexplored in the development of medications to assist with smoking cessation.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Corpus Striatum": true
        }
      },
      "source": 111,
      "target": 88,
      "key": "c3614adef21d78bfa5b76d9a219d22d1777f11bc93961c162f81bca4f5ec1d1d08a5235befc235d058597eb7426c4da29448c27a7bbd3e848050bff1a346af07"
    },
    {
      "line": 648,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 11,
      "target": 13,
      "key": "9ec4d2242ea61be21c90e9df294bed2d441eaaa6382482d670280e031bb9dc32dcc9a21ad0af92db3d67f028f331ff9194e34c85ecc04b6bb784cb072e612ab3"
    },
    {
      "line": 655,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 11,
      "target": 93,
      "key": "1a6a1abed64587253af8764e2ed5b2afc53e8eb3fdd8fc5b97ddf4740397fb0686cc9b046cf4bcdeafa2290719359174b493fc502e746c91549a41e56ce44148"
    },
    {
      "line": 649,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 21,
      "target": 13,
      "key": "5f9e1708184037f157cde9f8d9c721b6227da9f1bc26647f26cd683a27eeabff7a340a5e449f695ceeb7eb41e1e53725d249a3063175c7f39f884a061f45fba9"
    },
    {
      "line": 656,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 21,
      "target": 93,
      "key": "98fdb66f0a91387f7c29186a31b7b544bdb022c5b42af733d066940563a7e2510e989fe2203af400a23688bed92a389ebb6d952c159856bba16541e6992d5293"
    },
    {
      "line": 650,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 18,
      "target": 13,
      "key": "07af5407fd9e93e043f1006216e8b37f932d398b3170cccb3f22aed671681d4c6dfed79f90c851dd76ca70566e5d7ef9ed823dd35a3d214bb3c74564801db753"
    },
    {
      "line": 657,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 18,
      "target": 93,
      "key": "3f2d9b76219d340e6ce8a987c5699bcfc5d6b158a79ddee6d95a6ea9a6d11249ad6430484fcfc38b13a9690305b54fa48d6f34564835c15fcdc57fa8e6625429"
    },
    {
      "line": 651,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 14,
      "target": 13,
      "key": "31eda312abbbf8be68e08d172f52b37d6146c1494319c973066a88bd6fc6661d792e169f29127480aa58b6736959e5bd55dfad423ce6bdbba90dcd13e1bde639"
    },
    {
      "line": 658,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 14,
      "target": 93,
      "key": "b3922cddfe640aab9e553cd9eebd4e9616875c35fcbad476df50e073d21f13321ca8c6cd862655a9efd55b6efd5853d7301b966ee2874d449ab7a52711265288"
    },
    {
      "line": 652,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 16,
      "target": 13,
      "key": "949852412177345b635d8bffd90ac296fec8363c04ad5faeff08a9cec9d03173a68677de760572b43228a9cc175133b72d1495033db42eee807f68fc8d776a08"
    },
    {
      "line": 659,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 16,
      "target": 93,
      "key": "e04ba4fc894bd675b4e92f88701c07f9df0d13ebc0ac91001bb1c86ab5bcb54ca5bf577d85e048a9159c9afe97dc8d0f08728ac7f900dde179396af1d9168db3"
    },
    {
      "line": 653,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 17,
      "target": 13,
      "key": "4cc38a44f416074a15a0653b17c69817ade41e541b4b046243ed003b3bb215e08be1418834711185b66bbd1255f3dca2c7979203c949cc234fb46a72a40d03ec"
    },
    {
      "line": 660,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 17,
      "target": 93,
      "key": "cea19c73728eb861cd0ea28620882329f520c25c54e6b425b7b86e79008475cf47175f58e0796a3c9c5af5aceca2c2145d36fd150dc664f938916b92fb792e90"
    },
    {
      "line": 654,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "source": 23,
      "target": 13,
      "key": "af3d282a5bf0132220f78369da3c85c8295ea6e471db779558923fd2fe05f370b94532c20aad5b0f59159f832ebfa4cdc828caa71b18bc85811d05e9622b7165"
    },
    {
      "line": 661,
      "relation": "decreases",
      "evidence": "Meanwhile, a number of key antidepressants, such as fluoxetine (Prozac; lilly), sertraline (Zoloft; Pfizer), paroxetine (Paxil/Seroxat; Novo Nordisk/GlaxoSmithKline), nefazodone, nisoxetine, citalopram (Celexa/Cipramil/Cipram; H. lundbeck), nomifensine and vanoxerine211–216 were shown to inhibit neuronal nAChRs, in addition to inhibiting selective monoamine reuptake.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 23,
      "target": 93,
      "key": "623fcb7ba83ccf08b576731064975b600a55dbadb84d950ec07ebbca247b308bfef21a5feb4a3877532a87edd195f87c9eb423ec3e2dfb217d51a2c24645404e"
    },
    {
      "line": 672,
      "relation": "increases",
      "evidence": "using in vivo proton NMR imaging, levels of choline (the rate-limiting precursor to endogeneous ACh) were shown to be increased in the brains of patients with depression217 and in the prefrontal cortex of adolescents with depression218 compared with the control group.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Prefrontal Cortex": true
        }
      },
      "source": 106,
      "target": 8,
      "key": "f74d52f64019a87865a01f427646d97155b03c9faf1992575563d16f339f66add5288463a1647a258580af567881a39a50044a770215835fc3c7b82bb1041078"
    },
    {
      "line": 697,
      "relation": "regulates",
      "evidence": "Also, α7- and non-α7-containing nicotinic receptors directly or indirectly (through GABAergic interneurons) modulate serotonin release in spinal cord slices230. However, the identity of the receptors that are responsible for the spinal control of nociception is currently unknown. in this process, the nicotine-induced antinociception seems to be mediated primarily by activation of calcium– calmodulin-dependent protein kinase 2, but this is not the case for supraspinal nociception control229.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GOCC",
            "name": "intracellular"
          },
          "toLoc": {
            "namespace": "GOCC",
            "name": "extracellular space"
          }
        }
      },
      "source": 37,
      "target": 20,
      "key": "6af544ee65ed2ea2f2c537a372482a08ce50fc1517e826555efed9ef54c3f7087dbab5e0a20ccc15d661b4efb5702aa8f1a99acd5228ec77fc00e8d37f24d9a1"
    },
    {
      "line": 698,
      "relation": "increases",
      "evidence": "Also, α7- and non-α7-containing nicotinic receptors directly or indirectly (through GABAergic interneurons) modulate serotonin release in spinal cord slices230. However, the identity of the receptors that are responsible for the spinal control of nociception is currently unknown. in this process, the nicotine-induced antinociception seems to be mediated primarily by activation of calcium– calmodulin-dependent protein kinase 2, but this is not the case for supraspinal nociception control229.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 64,
      "target": 15,
      "key": "6d38ffbc5e35e09f59ddee3d5a2a5d92fa4d78e1918275ddc00b488d2233f5bbe7a7ce97cfa5e3d871001dd711b36ae43da1a066c7fadef9a6c69b08fd2599f9"
    },
    {
      "line": 713,
      "relation": "increases",
      "evidence": "The first nicotinic receptor ligand to undergo Phase ii clinical trials for analgesic activity was the potent Abbott compound ABT-594, a nAChR agonist that preferentially targets α4β2 (ReFS 231–235). The compound allowed for the clinical proof of concept, but could not be developed further because of adverse effects such as emesis and nausea236. As these adverse effects seemed to be attributable to the activation of the ganglionic α3β4 nAChR receptors, Abbott undertook a search for more selective α4β2 agonists, independently and in cooperation with Neurosearch.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 30,
      "target": 70,
      "key": "7c4dc0af2be084945334fc0a809e1ca2377c0236aeaac3a537f18601b2d08b85059a9ca639554c30d154d1f256639bdb10d3a38070cd36c42c157fee83cbfed5"
    },
    {
      "line": 714,
      "relation": "association",
      "evidence": "The first nicotinic receptor ligand to undergo Phase ii clinical trials for analgesic activity was the potent Abbott compound ABT-594, a nAChR agonist that preferentially targets α4β2 (ReFS 231–235). The compound allowed for the clinical proof of concept, but could not be developed further because of adverse effects such as emesis and nausea236. As these adverse effects seemed to be attributable to the activation of the ganglionic α3β4 nAChR receptors, Abbott undertook a search for more selective α4β2 agonists, independently and in cooperation with Neurosearch.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 30,
      "target": 113,
      "key": "f5a1ff91a252571e2afa20faaef2d5b5e37d55558823e01faf0f24dedc17250cc4230dbdfe8279725f15191923a43ab602449f761d0c1cc679426a7e8e56e6f0"
    },
    {
      "line": 715,
      "relation": "association",
      "evidence": "The first nicotinic receptor ligand to undergo Phase ii clinical trials for analgesic activity was the potent Abbott compound ABT-594, a nAChR agonist that preferentially targets α4β2 (ReFS 231–235). The compound allowed for the clinical proof of concept, but could not be developed further because of adverse effects such as emesis and nausea236. As these adverse effects seemed to be attributable to the activation of the ganglionic α3β4 nAChR receptors, Abbott undertook a search for more selective α4β2 agonists, independently and in cooperation with Neurosearch.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 30,
      "target": 108,
      "key": "447e6277db0eb87a944c18085c4fd71ea27c65fab88a4ad90ff8d6b06a6d9edf3f079404b4bd8009a2f09f9568546063818e528362b36beee56f1582d88fa590"
    },
    {
      "line": 716,
      "relation": "increases",
      "evidence": "The first nicotinic receptor ligand to undergo Phase ii clinical trials for analgesic activity was the potent Abbott compound ABT-594, a nAChR agonist that preferentially targets α4β2 (ReFS 231–235). The compound allowed for the clinical proof of concept, but could not be developed further because of adverse effects such as emesis and nausea236. As these adverse effects seemed to be attributable to the activation of the ganglionic α3β4 nAChR receptors, Abbott undertook a search for more selective α4β2 agonists, independently and in cooperation with Neurosearch.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 30,
      "target": 55,
      "key": "ed99fe23801b5a6b5fa1a5aa81890b10e0275a7007bfd1b48759a605aced16c3178e05e2d702ae1d8567b41a58f2a44edba8a05abf768254852c1fb18b887c26"
    },
    {
      "line": 714,
      "relation": "association",
      "evidence": "The first nicotinic receptor ligand to undergo Phase ii clinical trials for analgesic activity was the potent Abbott compound ABT-594, a nAChR agonist that preferentially targets α4β2 (ReFS 231–235). The compound allowed for the clinical proof of concept, but could not be developed further because of adverse effects such as emesis and nausea236. As these adverse effects seemed to be attributable to the activation of the ganglionic α3β4 nAChR receptors, Abbott undertook a search for more selective α4β2 agonists, independently and in cooperation with Neurosearch.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 113,
      "target": 30,
      "key": "d03d736dc43c5c77f1b56b56002d658fdc392eb3421aff83af2ca8b5fef07148cfe10e38616cd4be243eaf76efbd29214415d1fa21cdb2ee46760544146a7e1a"
    },
    {
      "line": 715,
      "relation": "association",
      "evidence": "The first nicotinic receptor ligand to undergo Phase ii clinical trials for analgesic activity was the potent Abbott compound ABT-594, a nAChR agonist that preferentially targets α4β2 (ReFS 231–235). The compound allowed for the clinical proof of concept, but could not be developed further because of adverse effects such as emesis and nausea236. As these adverse effects seemed to be attributable to the activation of the ganglionic α3β4 nAChR receptors, Abbott undertook a search for more selective α4β2 agonists, independently and in cooperation with Neurosearch.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 108,
      "target": 30,
      "key": "167cda4b883368a2009306a76c8ea1de27555de5c8513b3ff4b8083b017eeee03c02978241b268893067fb226cba94d6540c1c87df151faffabc408ec501767f"
    },
    {
      "relation": "hasComponent",
      "source": 55,
      "target": 76,
      "key": "d727c5aca38ebe1807634c1ba6bb097b0317c5395e9da3883290b2feab7d96de09f18d2db3a93382c7495307f0f2856a1ca1d34047af68aa9c35097d0409ce57"
    },
    {
      "relation": "hasComponent",
      "source": 55,
      "target": 88,
      "key": "03719d6779515381eae4586d781dc2d532b70631be0be99689c4c358720a1ed00a8f36266d2ee221680a03593f2446e7f67a6502945eec8260c1a897da44af37"
    },
    {
      "line": 727,
      "relation": "increases",
      "evidence": "Both initiatives were successful: new compounds — A-366833 and ABT-894 — with improved α4β2 selectivity and a broad spectrum of analgesic efficacy without adverse effects were identified236. ABT-894 was chosen to go into Phase ii clinical trials but the results were disappointing, and the development of this compound for neuropathic pain has been discontinued. The compound remains in clinical trials for ADHD.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 28,
      "target": 70,
      "key": "23d48fe89bdc8574da9f6762e2404065aa34d39811ff19309942ac4aa9493d341b3ce308e9da34f2dc2eb6f3b8ca3afbeac66869d42fd05f1446172271a75384"
    },
    {
      "relation": "hasComponent",
      "source": 54,
      "target": 74,
      "key": "3dbe005fd09a157aa884a02aae3c0659bbf009bcef0aa4f1033e9b5f4140331a91c9c5f74ee6e376c09db67f8c928bca3a45ef8a4133272d67cbee85cbe62eec"
    },
    {
      "relation": "hasComponent",
      "source": 54,
      "target": 85,
      "key": "f9a0d44d06280b42306670631563833fa65915f893f3778e7b193281f334507a1c8e0487c80c3040f0394cb8e4efe2e182feafabed1a84f239a7ba00e0a4711a"
    },
    {
      "line": 736,
      "relation": "association",
      "evidence": "Regarding the ascending afferent excitatory pain pathway, in which nicotinic antagonists are anticipated to have analgesic effects, a newly described subtype of nAChR, α9α10, seems to be expressed on dorsal root ganglia (in addition to the inner ear) and constitutes an in vitro target for new α-conotoxins, such as vc1.1, RgiA, or it14a237–241.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 54,
      "target": 40,
      "key": "20ca40d7fc215165237f5cb01324569aca4ed55d4c6c64f31f16a1284dae25383b504730c94c563cb88a76dad468ee29558728573a8606f6c4b9393c04f042b5"
    },
    {
      "line": 744,
      "relation": "increases",
      "evidence": "In vivo, these α-conotoxins display potent alleviation of allopathic pain239,242,243 (and additionally reveal an endogeneous ACh activation of lymphocytes through α9α10 nAChRs, which are inhibited by these α-conotoxins).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 54,
      "target": 42,
      "key": "a58d09a605c2d849b88a45f1ff003b8a07fbd8f9bbbf5d79cdd6f06ad83b56ba745a35a98fa36eb085e91b7274f3f925fe1d1c8a9d978aa72314f5e13e26028d"
    },
    {
      "line": 736,
      "relation": "association",
      "evidence": "Regarding the ascending afferent excitatory pain pathway, in which nicotinic antagonists are anticipated to have analgesic effects, a newly described subtype of nAChR, α9α10, seems to be expressed on dorsal root ganglia (in addition to the inner ear) and constitutes an in vitro target for new α-conotoxins, such as vc1.1, RgiA, or it14a237–241.",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 40,
      "target": 54,
      "key": "950b1fe79a7dad52306c96c0a57aadb8209da15c76493a37ecbc06e85d57e36c68501072b4909623b82ab17110782896f6c709c8d80f84e14129e6e565d1062c"
    },
    {
      "line": 745,
      "relation": "decreases",
      "evidence": "In vivo, these α-conotoxins display potent alleviation of allopathic pain239,242,243 (and additionally reveal an endogeneous ACh activation of lymphocytes through α9α10 nAChRs, which are inhibited by these α-conotoxins).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 40,
      "target": 54,
      "key": "3442fbbb5c2df08e60bc3654064bf137768649814dc0646d1d3bf9997b3aa7ec246c5cfb8a33ada24b0d98739fc9b66562d747ff28a25c8114fd5acc664cf819"
    },
    {
      "line": 743,
      "relation": "decreases",
      "evidence": "In vivo, these α-conotoxins display potent alleviation of allopathic pain239,242,243 (and additionally reveal an endogeneous ACh activation of lymphocytes through α9α10 nAChRs, which are inhibited by these α-conotoxins).",
      "citation": {
        "type": "PubMed",
        "reference": "19721446"
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 40,
      "target": 110,
      "key": "55e6463737374e8975cca1b6df779bd386ebea17245ef991a95258e06c97b8627b68f59fd5689b4b9ce3e916e2ebf61e0adf5985a102c09a88d21473472f20c0"
    }
  ]
}